

Diagnosis of cancer in Surrey

July 2024, updated March 2025

Produced by Daisy McInnerney PhD, Senior Public Health Programme Lead and Researcher, Surrey County Council

Stage at diagnosis

One of NHS England's CORE20Plus5 key clinical areas is early diagnosis of cancer, which defines the aim for 75% cancers to be diagnosed at an early stage (stage 1 or 2), when survival outcomes are better, by 2028

About the data source

[Rapid Cancer Registration Data \(RCRD\)](#)

The information below is copied directly from the database above. For full information see [Rapid Cancer Registration Data \(RCRD\)](#)

Introduction

Rapid Cancer Registration Data (RCRD) provides a quick, indicative source of cancer data. It is provided to support the planning and provision of cancer services. The data is based on a rapid processing of cancer registration data sources, in particular the Cancer Outcomes and Services Dataset (COSD) information. In comparison, National Cancer Registration Data (NCRD) relies on additional data sources, enhanced follow-up with trusts and expert processing by cancer registration officers. This tool provides cancer incidence, early-stage proportion and treatment proportion data, derived from RCRD. Please read the [Uses and Limitations](#) page for details of how this can be used and how it compares to NCRD.

Data timeliness

The most recent update, released on 30 January 2025, is based on data available by 11 January 2025.

For this release, data is estimated to be near-complete for months up to:

It is therefore important to note that the data is not 100% complete, particularly for diagnoses and treatments in more recent months.

Type of data	Data source	Latest month with near-completeness
Diagnoses (incidence), including stage	COSD, HES, CWT, Death Certificates from ONS	October 2024, although with slightly lower completeness from August 2024 onwards
Surgical tumour resections	HES, COSD	July 2024
Chemotherapy	SACT	March 2024
Radiotherapy	RTDS	November 2024

Variations by demographics (gender, age, ethnicity, deprivation) are only available at a national not ICB level.

Rapid cancer registration data: proportion of cancers diagnosed at Stage 1/2 early stage proportions, 12 months to October 2024: Surrey Heartlands

Geography	Year	Date	Cancer group	Metric	Data completeness (12m)	Numerator (12m)	Denominator (12m)	Statistic (12m)	
NHS Surrey Heartlands Integrated Care Board	2024	Oct-24	Brain and CNS	Early stage proportion	Complete	NA	NA	NA	
NHS Surrey Heartlands Integrated Care Board	2024	Oct-24	Head and Neck	Early stage proportion	Complete	NA	NA	NA	
			Lip, oral cavity and pharynx						
NHS Surrey Heartlands Integrated Care Board	2024	Oct-24	pharynx	Early stage proportion	Complete	NA	NA	NA	
NHS Surrey Heartlands Integrated Care Board	2024	Oct-24	Liver	Early stage proportion	Complete		0	0NA	
NHS Surrey Heartlands Integrated Care Board	2024	Oct-24	Multiple myeloma	Early stage proportion	Complete		0	0NA	
NHS Surrey Heartlands Integrated Care Board	2024	Oct-24	Unknown	Early stage proportion	Complete	NA	NA	NA	
NHS Surrey Heartlands Integrated Care Board	2024	Oct-24	Melanoma	Early stage proportion	Complete		293	311	94.2
NHS Surrey Heartlands Integrated Care Board	2024	Oct-24	Breast	Early stage proportion	Complete		675	793	85.1
NHS Surrey Heartlands Integrated Care Board	2024	Oct-24	Uterine	Early stage proportion	Complete		106	135	78.5
NHS Surrey Heartlands Integrated Care Board	2024	Oct-24	Bladder	Early stage proportion	Complete		95	131	72.5
NHS Surrey Heartlands Integrated Care Board	2024	Oct-24	Prostate	Early stage proportion	Complete		743	1079	68.9
NHS Surrey Heartlands Integrated Care Board	2024	Oct-24	Gynaecological	Early stage proportion	Complete		131	201	65.2
NHS Surrey Heartlands Integrated Care Board	2024	Oct-24	All sites combined	Early stage proportion	Complete		2634	4175	63.1
			Urological excl						
NHS Surrey Heartlands Integrated Care Board	2024	Oct-24	prostate	Early stage proportion	Complete		177	283	62.5
NHS Surrey Heartlands Integrated Care Board	2024	Oct-24	Kidney	Early stage proportion	Complete		82	152	53.9
NHS Surrey Heartlands Integrated Care Board	2024	Oct-24	Colorectal	Early stage proportion	Complete		278	581	47.8
NHS Surrey Heartlands Integrated Care Board	2024	Oct-24	Haematological	Early stage proportion	Complete		62	154	40.3
NHS Surrey Heartlands Integrated Care Board	2024	Oct-24	Lung	Early stage proportion	Complete		199	501	39.7
NHS Surrey Heartlands Integrated Care Board	2024	Oct-24	Ovarian	Early stage proportion	Complete		25	66	37.9
			Non-Hodgkin						
NHS Surrey Heartlands Integrated Care Board	2024	Oct-24	lymphoma	Early stage proportion	Complete		45	125	36
NHS Surrey Heartlands Integrated Care Board	2024	Oct-24	Oesophageal	Early stage proportion	Complete		32	111	28.8
NHS Surrey Heartlands Integrated Care Board	2024	Oct-24	Oesophago-gastric	Early stage proportion	Complete		42	149	28.2
NHS Surrey Heartlands Integrated Care Board	2024	Oct-24	Pancreatic	Early stage proportion	Complete		34	123	27.6
NHS Surrey Heartlands Integrated Care Board	2024	Oct-24	Upper GI excl OG	Early stage proportion	Complete		34	123	27.6

Topline overview

In Surrey Heartlands ICB, the proportion of early stage diagnoses ranged by cancer type from 28% for upper GI (excl OG) to 94% for melanoma. The value for all sites combined was 63%, which is higher than England (59%) but below the CORE20Plus5 75% target.

Of the cancers with data showing early stage proportions, the highest proportion of early diagnoses are seen in melanoma (94%), breast (85%), uterine (79%) and bladder (73%). The lowest proportions of early diagnosis are seen for upper GI cancers excluding oesophago-gastric cancers (28%), pancreatic (28%), oesophago-gastric cancers (28%), oesophageal (29%) non-Hodgkin lymphoma (36%), ovarian cancer (38%) and lung (40%).

Rapid cancer registration data: proportion of cancers diagnosed at Stage 1/2 early stage proportions, 12 months to October 2024: Frimley ICB

Geography	Year	Date	Cancer group	Metric	Data completeness	Numerator (12m)	Denominator (12m)	Statistic (12m)	
NHS Frimley Integrated Care Board	2024	Oct-24	Brain and CNS	Early stage proportion	Complete	NA	NA	NA	
NHS Frimley Integrated Care Board	2024	Oct-24	Head and Neck	Early stage proportion	Complete	NA	NA	NA	
NHS Frimley Integrated Care Board	2024	Oct-24	Lip, oral cavity and pharynx	Early stage proportion	Complete	NA	NA	NA	
NHS Frimley Integrated Care Board	2024	Oct-24	Liver	Early stage proportion	Complete		0	0 NA	
NHS Frimley Integrated Care Board	2024	Oct-24	Multiple myeloma	Early stage proportion	Complete		0	0 NA	
NHS Frimley Integrated Care Board	2024	Oct-24	Unknown	Early stage proportion	Complete	NA	NA	NA	
NHS Frimley Integrated Care Board	2024	Oct-24	Melanoma	Early stage proportion	Complete		189	198	95.5
NHS Frimley Integrated Care Board	2024	Oct-24	Bladder	Early stage proportion	Complete		60	69	87
NHS Frimley Integrated Care Board	2024	Oct-24	Breast	Early stage proportion	Complete		446	514	86.8
NHS Frimley Integrated Care Board	2024	Oct-24	Uterine	Early stage proportion	Complete		90	118	76.3
NHS Frimley Integrated Care Board	2024	Oct-24	Urological excl prostate	Early stage proportion	Complete		163	227	71.8
NHS Frimley Integrated Care Board	2024	Oct-24	Gynaecological	Early stage proportion	Complete		117	167	70.1
NHS Frimley Integrated Care Board	2024	Oct-24	Kidney	Early stage proportion	Complete		103	158	65.2
NHS Frimley Integrated Care Board	2024	Oct-24	All sites combined	Early stage proportion	Complete		1695	2805	60.4
NHS Frimley Integrated Care Board	2024	Oct-24	Ovarian	Early stage proportion	Complete		27	49	55.1
NHS Frimley Integrated Care Board	2024	Oct-24	Colorectal	Early stage proportion	Complete		225	423	53.2
NHS Frimley Integrated Care Board	2024	Oct-24	Prostate	Early stage proportion	Complete		308	587	52.5
NHS Frimley Integrated Care Board	2024	Oct-24	Haematological	Early stage proportion	Complete		42	99	42.4
NHS Frimley Integrated Care Board	2024	Oct-24	Non-Hodgkin lymphoma	Early stage proportion	Complete		37	91	40.7
NHS Frimley Integrated Care Board	2024	Oct-24	Lung	Early stage proportion	Complete		150	393	38.2
NHS Frimley Integrated Care Board	2024	Oct-24	Pancreatic	Early stage proportion	Complete		30	91	33
NHS Frimley Integrated Care Board	2024	Oct-24	Upper GI excl OG	Early stage proportion	Complete		30	91	33
NHS Frimley Integrated Care Board	2024	Oct-24	Oesophago-gastric	Early stage proportion	Complete		25	106	23.6
NHS Frimley Integrated Care Board	2024	Oct-24	Oesophageal	Early stage proportion	Complete		18	80	22.5

Topline overview

In Frimley ICB, the proportion of early stage diagnoses ranged by cancer type from 28% for upper GI (excl OG) to 94% for melanoma. The value for all sites combined was 60%, which is higher than England (59%) but below the CORE20Plus5 75% target.

Of the cancers with data showing early stage proportions, the highest proportion of early diagnoses are seen in melanoma (96%), bladder (86%), breast (87%), uterine (76%). The lowest proportions of early diagnosis are seen for oesophageal (23%), oesophago-gastric cancers (24%), upper-GI exc. Oesophago-gastric (33%), pancreatic (33%) and lung (38%).

Rapid cancer registration data: proportion of cancers diagnosed at Stage 1/2 early stage proportions, 12 months to October 2024: NATIONAL (England)

Geography	Year	Date	Cancer group	Metric	Data completeness	Numerator (12m)	Denominator (12m)	Statistic (12m)
England	2024	Oct-24	Bone and soft tissue	Early stage proportion	Complete	NA	NA	NA
England	2024	Oct-24	Brain and CNS	Early stage proportion	Complete	NA	NA	NA
England	2024	Oct-24	Cervical	Early stage proportion	Complete		0	0 NA
England	2024	Oct-24	Endocrine	Early stage proportion	Complete	NA	NA	NA
England	2024	Oct-24	Head and Neck	Early stage proportion	Complete	NA	NA	NA
England	2024	Oct-24	Lip, oral cavity and pharynx	Early stage proportion	Complete	NA	NA	NA
England	2024	Oct-24	Liver	Early stage proportion	Complete		0	0 NA
England	2024	Oct-24	Lymphoid leukaemia	Early stage proportion	Complete		0	0 NA
England	2024	Oct-24	Multiple myeloma	Early stage proportion	Complete		0	0 NA
England	2024	Oct-24	Myeloid leukaemia	Early stage proportion	Complete		0	0 NA
England	2024	Oct-24	Nasal cavity, sinuses and larynx	Early stage proportion	Complete	NA	NA	NA
England	2024	Oct-24	Testicular	Early stage proportion	Complete		0	0 NA
England	2024	Oct-24	Unknown	Early stage proportion	Complete	NA	NA	NA
England	2024	Oct-24	Melanoma	Early stage proportion	Complete		14017	14874 94.2
England	2024	Oct-24	Breast	Early stage proportion	Complete		32502	37974 85.6
England	2024	Oct-24	Bladder	Early stage proportion	Complete		4749	5865 81
England	2024	Oct-24	Uterine	Early stage proportion	Complete		5569	7147 77.9
England	2024	Oct-24	Urological excl prostate	Early stage proportion	Complete		9270	13465 68.8
England	2024	Oct-24	Gynaecological	Early stage proportion	Complete		7099	10648 66.7
England	2024	Oct-24	Kidney	Early stage proportion	Complete		4521	7600 59.5
England	2024	Oct-24	All sites combined	Early stage proportion	Complete		126616	215681 58.7
England	2024	Oct-24	Prostate	Early stage proportion	Complete		27770	50179 55.3
England	2024	Oct-24	Colorectal	Early stage proportion	Complete		14806	30509 48.5
England	2024	Oct-24	Hodgkin lymphoma	Early stage proportion	Complete		542	1156 46.9
England	2024	Oct-24	Ovarian	Early stage proportion	Complete		1530	3501 43.7
England	2024	Oct-24	Lung	Early stage proportion	Complete		14273	35797 39.9
England	2024	Oct-24	Haematological	Early stage proportion	Complete		2339	6767 34.6
England	2024	Oct-24	Stomach	Early stage proportion	Complete		845	2554 33.1
England	2024	Oct-24	Non-Hodgkin lymphoma	Early stage proportion	Complete		1651	5252 31.4
England	2024	Oct-24	Oesophago-gastric	Early stage proportion	Complete		2899	9450 30.7
England	2024	Oct-24	Oesophageal	Early stage proportion	Complete		2054	6896 29.8
England	2024	Oct-24	Pancreatic	Early stage proportion	Complete		1641	6018 27.3
England	2024	Oct-24	Upper GI excl OG	Early stage proportion	Complete		1641	6018 27.3

Topline overview

In England, the proportion of early stage diagnoses ranged by cancer type from 27% for upper GI (excl OG) to 94% for melanoma. This is a similar range to that seen in Surrey Heartlands and Frimley ICB. The value for all sites combined was 59%, which is lower than both Surrey Heartlands and Frimley, and lower than the 75% CORE20Plus5 target.

Of the cancers with data showing early stage proportions, the highest proportion of early diagnoses are seen in melanoma (96%), bladder (86%), breast (87%), uterine (76%). The lowest proportions of early diagnosis are seen for oesophageal (23%), oesophago-gastric cancers (24%), upper-GI exc. Oesophago-gastric (33%), pancreatic (33%) and lung (38%).

Rapid cancer registration data: variations in proportion of cancers diagnosed at Stage 1/2, 12 months to October 2024: NATIONAL (England) by age

Topline overview

The table only shows cancer types for which data was available.

For most cancer sites, a higher proportion are diagnosed at S1/2 in younger compared to older adults. This difference is largest for **ovarian** (71% age 0-49 vs 25% age 80+) and **prostate** cancers (79% age 0-49 vs 30% age 80+). The inverse pattern is seen for **bladder** (83% 80+ vs 69% age 0-49), **oesophageal** (33% 80+ vs 22% 0-49), **colorectal** (50% age 80+ vs 41.1% age 0-49), **lung** (42% 60-69 vs 31% 0-49) and **stomach** (37% age 80+ vs 28% age 50-59) cancers - where a higher proportion of older adults are diagnosed at an early stage compared to younger adults.

Year	Month	Cancer group	Metric	Breakdown	Demographic	Data completeness	Numerator (12m)	Denominator (12m)	Statistic (12m)	0-49 minus 80+
2024	October	All sites combined	Early stage proportion	Age-group	0-49	Complete	11156	18205	68.8	16.6
2024	October	All sites combined	Early stage proportion	Age-group	50-59	Complete	20969	31474	66.6	
2024	October	All sites combined	Early stage proportion	Age-group	60-69	Complete	35544	57947	61.3	
2024	October	All sites combined	Early stage proportion	Age-group	70-79	Complete	37732	69444	54.3	
2024	October	All sites combined	Early stage proportion	Age-group	80+	Complete	21215	40611	52.2	
2024	October	Bladder	Early stage proportion	Age-group	0-49	Complete	88	127	69.3	-13.8
2024	October	Bladder	Early stage proportion	Age-group	50-59	Complete	341	448	76.1	
2024	October	Bladder	Early stage proportion	Age-group	60-69	Complete	879	1107	79.4	
2024	October	Bladder	Early stage proportion	Age-group	70-79	Complete	1773	2176	81.5	
2024	October	Bladder	Early stage proportion	Age-group	80+	Complete	1668	2007	83.1	0.3
2024	October	Breast	Early stage proportion	Age-group	0-49	Complete	5022	6194	81.1	
2024	October	Breast	Early stage proportion	Age-group	50-59	Complete	7761	8820	88	
2024	October	Breast	Early stage proportion	Age-group	60-69	Complete	8883	9646	90	
2024	October	Breast	Early stage proportion	Age-group	70-79	Complete	6446	7636	84.4	
2024	October	Breast	Early stage proportion	Age-group	80+	Complete	4590	5078	80.8	
2024	October	Cervical	Early stage proportion	Age-group	0-49	Complete	0	0	0	0
2024	October	Cervical	Early stage proportion	Age-group	50-59	Complete	0	0	0	0
2024	October	Cervical	Early stage proportion	Age-group	60-69	Complete	0	0	0	0
2024	October	Cervical	Early stage proportion	Age-group	70-79	Complete	0	0	0	0
2024	October	Cervical	Early stage proportion	Age-group	80+	Complete	0	0	0	0
2024	October	Colorectal	Early stage proportion	Age-group	0-49	Complete	1019	2480	41.1	-9.4
2024	October	Colorectal	Early stage proportion	Age-group	50-59	Complete	1892	4217	44.9	
2024	October	Colorectal	Early stage proportion	Age-group	60-69	Complete	3268	6852	47.7	
2024	October	Colorectal	Early stage proportion	Age-group	70-79	Complete	4828	9397	51.4	
2024	October	Colorectal	Early stage proportion	Age-group	80+	Complete	3799	7563	50.2	
2024	October	Gynaecological	Early stage proportion	Age-group	0-49	Complete	987	1296	76.2	21.6
2024	October	Gynaecological	Early stage proportion	Age-group	50-59	Complete	1921	2181	73.4	
2024	October	Gynaecological	Early stage proportion	Age-group	60-69	Complete	2062	3006	68.6	
2024	October	Gynaecological	Early stage proportion	Age-group	70-79	Complete	1713	2818	60.8	
2024	October	Gynaecological	Early stage proportion	Age-group	80+	Complete	736	1347	54.6	
2024	October	Haematological	Early stage proportion	Age-group	0-49	Complete	545	1220	44.7	11.6
2024	October	Haematological	Early stage proportion	Age-group	50-59	Complete	328	598	35.5	
2024	October	Haematological	Early stage proportion	Age-group	60-69	Complete	495	1502	33	
2024	October	Haematological	Early stage proportion	Age-group	70-79	Complete	572	1918	29.8	
2024	October	Haematological	Early stage proportion	Age-group	80+	Complete	399	1204	33.1	
2024	October	Hodgkin lymphoma	Early stage proportion	Age-group	0-49	Complete	347	667	52	25
2024	October	Hodgkin lymphoma	Early stage proportion	Age-group	50-59	Complete	71	143	49.7	
2024	October	Hodgkin lymphoma	Early stage proportion	Age-group	60-69	Complete	66	139	47.5	
2024	October	Hodgkin lymphoma	Early stage proportion	Age-group	70-79	Complete	41	144	28.5	
2024	October	Hodgkin lymphoma	Early stage proportion	Age-group	80+	Complete	17	63	27	
2024	October	Kidney	Early stage proportion	Age-group	0-49	Complete	519	747	69.5	11.3
2024	October	Kidney	Early stage proportion	Age-group	50-59	Complete	831	1400	59.4	
2024	October	Kidney	Early stage proportion	Age-group	60-69	Complete	1249	2249	55.6	
2024	October	Kidney	Early stage proportion	Age-group	70-79	Complete	1301	2254	57.7	
2024	October	Kidney	Early stage proportion	Age-group	80+	Complete	630	1082	58.2	
2024	October	Liver	Early stage proportion	Age-group	0-49	Complete	0	0	0	0
2024	October	Liver	Early stage proportion	Age-group	50-59	Complete	0	0	0	0
2024	October	Liver	Early stage proportion	Age-group	60-69	Complete	0	0	0	0
2024	October	Liver	Early stage proportion	Age-group	70-79	Complete	0	0	0	0
2024	October	Liver	Early stage proportion	Age-group	80+	Complete	0	0	0	0
2024	October	Lung	Early stage proportion	Age-group	0-49	Complete	233	760	30.7	-8.1
2024	October	Lung	Early stage proportion	Age-group	50-59	Complete	989	2986	33.1	
2024	October	Lung	Early stage proportion	Age-group	60-69	Complete	3759	8951	42	
2024	October	Lung	Early stage proportion	Age-group	70-79	Complete	5746	13967	41.1	
2024	October	Lung	Early stage proportion	Age-group	80+	Complete	3546	9133	38.8	
2024	October	Lymphoid leukaemia	Early stage proportion	Age-group	0-49	Complete	0	0	0	0
2024	October	Lymphoid leukaemia	Early stage proportion	Age-group	50-59	Complete	0	0	0	0
2024	October	Lymphoid leukaemia	Early stage proportion	Age-group	60-69	Complete	0	0	0	0
2024	October	Lymphoid leukaemia	Early stage proportion	Age-group	70-79	Complete	0	0	0	0
2024	October	Lymphoid leukaemia	Early stage proportion	Age-group	80+	Complete	0	0	0	0
2024	October	Melanoma	Early stage proportion	Age-group	0-49	Complete	2119	2224	95.3	1.9
2024	October	Melanoma	Early stage proportion	Age-group	50-59	Complete	2252	2383	94.5	
2024	October	Melanoma	Early stage proportion	Age-group	60-69	Complete	3032	3214	94.3	
2024	October	Melanoma	Early stage proportion	Age-group	70-79	Complete	3701	3933	94.1	
2024	October	Melanoma	Early stage proportion	Age-group	80+	Complete	2913	3120	93.4	

Year	Month	Cancer group	Metric	Breakdown	Demographic	Data completeness	Numerator (12m)	Denominator (12m)	Statistic (12m)	0-49 minus 80+
2024	October	Multiple myeloma	Early stage proportion	Age-group	0-49	Complete	0	0	0	0
2024	October	Multiple myeloma	Early stage proportion	Age-group	50-59	Complete	0	0	0	0
2024	October	Multiple myeloma	Early stage proportion	Age-group	60-69	Complete	0	0	0	0
2024	October	Multiple myeloma	Early stage proportion	Age-group	70-79	Complete	0	0	0	0
2024	October	Multiple myeloma	Early stage proportion	Age-group	80+	Complete	0	0	0	0
2024	October	Myeloid leukaemia	Early stage proportion	Age-group	0-49	Complete	0	0	0	0
2024	October	Myeloid leukaemia	Early stage proportion	Age-group	50-59	Complete	0	0	0	0
2024	October	Myeloid leukaemia	Early stage proportion	Age-group	60-69	Complete	0	0	0	0
2024	October	Myeloid leukaemia	Early stage proportion	Age-group	70-79	Complete	0	0	0	0
2024	October	Myeloid leukaemia	Early stage proportion	Age-group	80+	Complete	0	0	0	0
2024	October	Non-Hodgkin lymphoma	Early stage proportion	Age-group	0-49	Complete	184	526	35	1.8
2024	October	Non-Hodgkin lymphoma	Early stage proportion	Age-group	50-59	Complete	229	721	31.8	
2024	October	Non-Hodgkin lymphoma	Early stage proportion	Age-group	60-69	Complete	398	1278	31.1	
2024	October	Non-Hodgkin lymphoma	Early stage proportion	Age-group	70-79	Complete	488	1666	29.3	
2024	October	Non-Hodgkin lymphoma	Early stage proportion	Age-group	80+	Complete	352	1061	33.2	
2024	October	Oesophageal	Early stage proportion	Age-group	0-49	Complete	44	199	22.1	-11.3
2024	October	Oesophageal	Early stage proportion	Age-group	50-59	Complete	181	793	22.8	
2024	October	Oesophageal	Early stage proportion	Age-group	60-69	Complete	485	1736	27.9	
2024	October	Oesophageal	Early stage proportion	Age-group	70-79	Complete	808	2563	31.5	
2024	October	Oesophageal	Early stage proportion	Age-group	80+	Complete	536	1605	33.4	
2024	October	Oesophago-gastric	Early stage proportion	Age-group	0-49	Complete	100	374	26.7	-7.8
2024	October	Oesophago-gastric	Early stage proportion	Age-group	50-59	Complete	270	1113	24.3	
2024	October	Oesophago-gastric	Early stage proportion	Age-group	60-69	Complete	660	2303	28.7	
2024	October	Oesophago-gastric	Early stage proportion	Age-group	70-79	Complete	1067	3334	32	
2024	October	Oesophago-gastric	Early stage proportion	Age-group	80+	Complete	802	2326	34.5	
2024	October	Ovarian	Early stage proportion	Age-group	0-49	Complete	956	708	71.3	45
2024	October	Ovarian	Early stage proportion	Age-group	50-59	Complete	323	645	50.1	
2024	October	Ovarian	Early stage proportion	Age-group	60-69	Complete	327	839	39	
2024	October	Ovarian	Early stage proportion	Age-group	70-79	Complete	262	880	29.8	
2024	October	Ovarian	Early stage proportion	Age-group	80+	Complete	113	429	26.3	
2024	October	Pancreatic	Early stage proportion	Age-group	0-49	Complete	67	204	32.8	4.3
2024	October	Pancreatic	Early stage proportion	Age-group	50-59	Complete	172	674	25.5	
2024	October	Pancreatic	Early stage proportion	Age-group	60-69	Complete	378	1427	26.5	
2024	October	Pancreatic	Early stage proportion	Age-group	70-79	Complete	567	2111	26.9	
2024	October	Pancreatic	Early stage proportion	Age-group	80+	Complete	457	1602	28.5	
2024	October	Prostate	Early stage proportion	Age-group	0-49	Complete	457	579	78.9	48.7
2024	October	Prostate	Early stage proportion	Age-group	50-59	Complete	4529	6329	71.6	
2024	October	Prostate	Early stage proportion	Age-group	60-69	Complete	11088	17822	62.2	
2024	October	Prostate	Early stage proportion	Age-group	70-79	Complete	10018	19900	50.3	
2024	October	Prostate	Early stage proportion	Age-group	80+	Complete	1675	5549	30.2	
2024	October	Stomach	Early stage proportion	Age-group	0-49	Complete	96	175	54.7	-4.8
2024	October	Stomach	Early stage proportion	Age-group	50-59	Complete	328	928	35.3	
2024	October	Stomach	Early stage proportion	Age-group	60-69	Complete	175	567	30.9	
2024	October	Stomach	Early stage proportion	Age-group	70-79	Complete	259	771	33.6	
2024	October	Stomach	Early stage proportion	Age-group	80+	Complete	266	721	36.9	
2024	October	Testicular	Early stage proportion	Age-group	0-49	Complete	0	0	0	0
2024	October	Testicular	Early stage proportion	Age-group	50-59	Complete	0	0	0	0
2024	October	Testicular	Early stage proportion	Age-group	60-69	Complete	0	0	0	0
2024	October	Testicular	Early stage proportion	Age-group	70-79	Complete	0	0	0	0
2024	October	Testicular	Early stage proportion	Age-group	80+	Complete	0	0	0	0
2024	October	Upper GI excl OG	Early stage proportion	Age-group	0-49	Complete	67	204	32.8	4.3
2024	October	Upper GI excl OG	Early stage proportion	Age-group	50-59	Complete	172	674	25.5	
2024	October	Upper GI excl OG	Early stage proportion	Age-group	60-69	Complete	378	1427	26.5	
2024	October	Upper GI excl OG	Early stage proportion	Age-group	70-79	Complete	567	2111	26.9	
2024	October	Upper GI excl OG	Early stage proportion	Age-group	80+	Complete	457	1602	28.5	
2024	October	Urological excl prostate	Early stage proportion	Age-group	0-49	Complete	607	874	69.5	-4.8
2024	October	Urological excl prostate	Early stage proportion	Age-group	50-59	Complete	1172	1848	63.4	
2024	October	Urological excl prostate	Early stage proportion	Age-group	60-69	Complete	2119	3224	65.7	
2024	October	Urological excl prostate	Early stage proportion	Age-group	70-79	Complete	3074	4439	69.4	
2024	October	Urological excl prostate	Early stage proportion	Age-group	80+	Complete	2298	3089	74.4	
2024	October	Uterine	Early stage proportion	Age-group	0-49	Complete	482	588	82	14.1
2024	October	Uterine	Early stage proportion	Age-group	50-59	Complete	1278	1536	83.2	
2024	October	Uterine	Early stage proportion	Age-group	60-69	Complete	1735	2167	80.1	
2024	October	Uterine	Early stage proportion	Age-group	70-79	Complete	1451	1928	75.3	
2024	October	Uterine	Early stage proportion	Age-group	80+	Complete	918	623	67.9	

Rapid cancer registration data: variations in proportion of cancers diagnosed at Stage 1 / 2, 12 months to October 2024: NATIONAL (England) by ethnicity

Topline overview The table only shows cancer types for which data was available. Of the cancers with data showing early stage proportions, across all sites combined, similar proportions were diagnosed at an early stage across ethnic groups: 58% for people of white ethnicity; 60% for people of Black or Asian ethnicity; 61% for people of Unknown and Mixed or Other ethnicity. But patterns differ substantially by site. The largest differences between ethnic groups are seen for ovarian cancer (57% S1/2 Black VS 42% S1/2 White ethnicity); melanoma (94% S1/2 White VS 82% Black and Asian ethnicity); prostate cancer (66% S1/2 Mixed/Other VS 65% Black VS 54% White ethnicity); uterine cancer (78% S1/2 White vs 66% Black ethnicity); lung (43% Black VS 40% White VS 30% Unknown ethnicity); and colorectal cancer (49% White VS 38% Black ethnicity).

Year	Month	Cancer group	Metric	Breakdown	Demographic	Data completeness	Numerator (12m)	Denominator (12m)	Statistic (12m)	Difference from proportion in White ethnicity
2024	October	All sites combined	Early stage proportion	Ethnicity	Asian	Complete	3861	6480	59.6	-1.3
2024	October	All sites combined	Early stage proportion	Ethnicity	Black	Complete	3412	5703	59.8	-1.5
2024	October	All sites combined	Early stage proportion	Ethnicity	Mixed and Other	Complete	3216	5237	61.4	-3.1
2024	October	All sites combined	Early stage proportion	Ethnicity	Unknown	Complete	12589	20733	60.7	-2.4
2024	October	All sites combined	Early stage proportion	Ethnicity	White	Complete	103538	177528	58.3	
2024	October	Bladder	Early stage proportion	Ethnicity	Asian	Complete	95	114	83.3	-2.4
2024	October	Bladder	Early stage proportion	Ethnicity	Black	Complete	58	77	75.3	5.6
2024	October	Bladder	Early stage proportion	Ethnicity	Mixed and Other	Complete	105	128	82	-1.1
2024	October	Bladder	Early stage proportion	Ethnicity	Unknown	Complete	319	391	81.6	-0.7
2024	October	Bladder	Early stage proportion	Ethnicity	White	Complete	4172	5155	80.9	
2024	October	Breast	Early stage proportion	Ethnicity	Asian	Complete	1446	1782	81.1	5.1
2024	October	Breast	Early stage proportion	Ethnicity	Black	Complete	854	1088	78.5	7.7
2024	October	Breast	Early stage proportion	Ethnicity	Mixed and Other	Complete	966	1162	83.1	3.1
2024	October	Breast	Early stage proportion	Ethnicity	Unknown	Complete	3241	3783	85.7	0.5
2024	October	Breast	Early stage proportion	Ethnicity	White	Complete	25995	30159	86.2	
2024	October	Colorectal	Early stage proportion	Ethnicity	Asian	Complete	395	889	44.4	4.6
2024	October	Colorectal	Early stage proportion	Ethnicity	Black	Complete	231	602	38.4	10.6
2024	October	Colorectal	Early stage proportion	Ethnicity	Mixed and Other	Complete	305	647	47.1	1.9
2024	October	Colorectal	Early stage proportion	Ethnicity	Unknown	Complete	1429	2962	48.2	0.8
2024	October	Colorectal	Early stage proportion	Ethnicity	White	Complete	12446	25409	49	
2024	October	Gynaecological	Early stage proportion	Ethnicity	Asian	Complete	461	650	70.9	-4.9
2024	October	Gynaecological	Early stage proportion	Ethnicity	Black	Complete	193	305	63.3	2.7
2024	October	Gynaecological	Early stage proportion	Ethnicity	Mixed and Other	Complete	239	362	66	0
2024	October	Gynaecological	Early stage proportion	Ethnicity	Unknown	Complete	749	1060	70.7	-4.7
2024	October	Gynaecological	Early stage proportion	Ethnicity	White	Complete	5457	8271	66	
2024	October	Haematological	Early stage proportion	Ethnicity	Asian	Complete	136	370	36.8	-2.8
2024	October	Haematological	Early stage proportion	Ethnicity	Black	Complete	55	139	39.6	-5.6
2024	October	Haematological	Early stage proportion	Ethnicity	Mixed and Other	Complete	84	232	36.2	-2.2
2024	October	Haematological	Early stage proportion	Ethnicity	Unknown	Complete	248	692	35.8	-1.8
2024	October	Haematological	Early stage proportion	Ethnicity	White	Complete	1816	5334	34	
2024	October	Hodgkin lymphoma	Early stage proportion	Ethnicity	Asian	Complete	41	88	46.6	1.1
2024	October	Hodgkin lymphoma	Early stage proportion	Ethnicity	Black	Complete	16	40	40	7.7
2024	October	Hodgkin lymphoma	Early stage proportion	Ethnicity	Mixed and Other	Complete	33	59	55.9	-8.2
2024	October	Hodgkin lymphoma	Early stage proportion	Ethnicity	Unknown	Complete	62	151	41.1	6.6
2024	October	Hodgkin lymphoma	Early stage proportion	Ethnicity	White	Complete	390	818	47.7	
2024	October	Kidney	Early stage proportion	Ethnicity	Asian	Complete	184	292	63	-4.2
2024	October	Kidney	Early stage proportion	Ethnicity	Black	Complete	113	166	68.1	-9.3
2024	October	Kidney	Early stage proportion	Ethnicity	Mixed and Other	Complete	151	244	61.9	-3.1
2024	October	Kidney	Early stage proportion	Ethnicity	Unknown	Complete	369	604	61.1	-2.3
2024	October	Kidney	Early stage proportion	Ethnicity	White	Complete	3704	6294	58.8	
2024	October	Lung	Early stage proportion	Ethnicity	Asian	Complete	293	750	39.1	1.4
2024	October	Lung	Early stage proportion	Ethnicity	Black	Complete	297	688	43.2	-2.7
2024	October	Lung	Early stage proportion	Ethnicity	Mixed and Other	Complete	319	768	41.5	-1
2024	October	Lung	Early stage proportion	Ethnicity	Unknown	Complete	642	2153	29.8	10.7
2024	October	Lung	Early stage proportion	Ethnicity	White	Complete	12722	31438	40.5	
2024	October	Melanoma	Early stage proportion	Ethnicity	Asian	Complete	28	34	82.4	11.8
2024	October	Melanoma	Early stage proportion	Ethnicity	Black	Complete	23	28	82.1	12.1
2024	October	Melanoma	Early stage proportion	Ethnicity	Mixed and Other	Complete	176	194	90.7	3.5
2024	October	Melanoma	Early stage proportion	Ethnicity	Unknown	Complete	1629	1709	95.3	-1.1
2024	October	Melanoma	Early stage proportion	Ethnicity	White	Complete	12161	12909	94.2	
2024	October	Non-Hodgkin lymphoma	Early stage proportion	Ethnicity	Asian	Complete	86	265	32.5	-1.4
2024	October	Non-Hodgkin lymphoma	Early stage proportion	Ethnicity	Black	Complete	29	82	35.4	-4.3
2024	October	Non-Hodgkin lymphoma	Early stage proportion	Ethnicity	Mixed and Other	Complete	45	154	29.2	1.9
2024	October	Non-Hodgkin lymphoma	Early stage proportion	Ethnicity	Unknown	Complete	170	506	33.6	-2.5
2024	October	Non-Hodgkin lymphoma	Early stage proportion	Ethnicity	White	Complete	1321	4245	31.1	
2024	October	Oesophageal	Early stage proportion	Ethnicity	Asian	Complete	33	121	27.3	3.3
2024	October	Oesophageal	Early stage proportion	Ethnicity	Black	Complete	15	71	21.1	9.5
2024	October	Oesophageal	Early stage proportion	Ethnicity	Mixed and Other	Complete	17	77	22.1	8.5
2024	October	Oesophageal	Early stage proportion	Ethnicity	Unknown	Complete	106	482	22	8.6
2024	October	Oesophageal	Early stage proportion	Ethnicity	White	Complete	1883	6145	30.6	
2024	October	Oesophago-gastric	Early stage proportion	Ethnicity	Asian	Complete	87	245	35.5	-4.3
2024	October	Oesophago-gastric	Early stage proportion	Ethnicity	Black	Complete	58	180	32.2	-1
2024	October	Oesophago-gastric	Early stage proportion	Ethnicity	Mixed and Other	Complete	45	171	26.3	4.9
2024	October	Oesophago-gastric	Early stage proportion	Ethnicity	Unknown	Complete	145	647	22.4	8.8
2024	October	Oesophago-gastric	Early stage proportion	Ethnicity	White	Complete	2564	8207	31.2	
2024	October	Ovarian	Early stage proportion	Ethnicity	Asian	Complete	102	202	50.5	-8.1
2024	October	Ovarian	Early stage proportion	Ethnicity	Black	Complete	52	92	56.5	-14.1
2024	October	Ovarian	Early stage proportion	Ethnicity	Mixed and Other	Complete	55	123	44.7	-2.3
2024	October	Ovarian	Early stage proportion	Ethnicity	Unknown	Complete	148	317	46.7	-4.3
2024	October	Ovarian	Early stage proportion	Ethnicity	White	Complete	1173	2767	42.4	
2024	October	Pancreatic	Early stage proportion	Ethnicity	Asian	Complete	60	211	28.4	-0.9
2024	October	Pancreatic	Early stage proportion	Ethnicity	Black	Complete	35	138	25.4	2.1
2024	October	Pancreatic	Early stage proportion	Ethnicity	Mixed and Other	Complete	42	143	29.4	-1.9
2024	October	Pancreatic	Early stage proportion	Ethnicity	Unknown	Complete	103	427	24.1	3.4
2024	October	Pancreatic	Early stage proportion	Ethnicity	White	Complete	1401	5099	27.5	
2024	October	Prostate	Early stage proportion	Ethnicity	Asian	Complete	676	1143	59.1	-5.3
2024	October	Prostate	Early stage proportion	Ethnicity	Black	Complete	1495	2292	65.2	-11.4
2024	October	Prostate	Early stage proportion	Ethnicity	Mixed and Other	Complete	784	1186	66.1	-12.3
2024	October	Prostate	Early stage proportion	Ethnicity	Unknown	Complete	3715	6305	58.9	-5.1
2024	October	Prostate	Early stage proportion	Ethnicity	White	Complete	21100	39253	53.8	
2024	October	Stomach	Early stage proportion	Ethnicity	Asian	Complete	54	124	43.5	-10.5
2024	October	Stomach	Early stage proportion	Ethnicity	Black	Complete	43	109	39.4	-6.4
2024	October	Stomach	Early stage proportion	Ethnicity	Mixed and Other	Complete	28	94	29.8	3.2
2024	October	Stomach	Early stage proportion	Ethnicity	Unknown	Complete	39	165	23.6	9.4
2024	October	Stomach	Early stage proportion	Ethnicity	White	Complete	681	2062	33	
2024	October	Upper GI excl OG	Early stage proportion	Ethnicity	Asian	Complete	60	211	28.4	-0.9
2024	October	Upper GI excl OG	Early stage proportion	Ethnicity	Black	Complete	35	138	25.4	2.1
2024	October	Upper GI excl OG	Early stage proportion	Ethnicity	Mixed and Other	Complete	42	143	29.4	-1.9
2024	October	Upper GI excl OG	Early stage proportion	Ethnicity	Unknown	Complete	103	427	24.1	3.4
2024	October	Upper GI excl OG	Early stage proportion	Ethnicity	White	Complete	1401	5099	27.5	
2024	October	Urological excl prostate	Early stage proportion	Ethnicity	Asian	Complete	279	406	68.7	0.1
2024	October	Urological excl prostate	Early stage proportion	Ethnicity	Black	Complete	171	243	70.4	-1.6
2024	October	Urological excl prostate	Early stage proportion	Ethnicity	Mixed and Other	Complete	256	372	68.8	0
2024	October	Urological excl prostate	Early stage proportion	Ethnicity	Unknown	Complete	688	995	69.1	-0.3
2024	October	Urological excl prostate	Early stage proportion	Ethnicity	White	Complete	7876	11449	68.8	
2024	October	Uterine	Early stage proportion	Ethnicity	Asian	Complete	359	448	80.1	-2.3
2024	October	Uterine	Early stage proportion	Ethnicity	Black	Complete	141	213	66.2	11.6
2024	October	Uterine	Early stage proportion	Ethnicity	Mixed and Other	Complete	184	239	77	0.8
2024	October	Uterine	Early stage proportion	Ethnicity	Unknown	Complete	601	743	80.9	-3.1
2024	October	Uterine	Early stage proportion	Ethnicity	White	Complete	4284	5504	77.8	

Rapid cancer registration data: variations in proportion of cancers diagnosed at Stage 1 / 2, 12 months to October 2024: NATIONAL (England) by deprivation

Topline overview The table only shows cancer types for which data was available. Of the cancers with data showing early stage proportions, across all sites combined, similar proportions were diagnosed at an early stage across ethnic groups: 58% for people of white ethnicity; 60% for people of Black or Asian ethnicity; 61% for people of Unknown and Mixed or Other ethnicity. But patterns differ substantially by site. The largest differences between ethnic groups are seen for ovarian cancer (57% S1/2 Black VS 42% S1/2 White ethnicity); melanoma (94% S1/2 White VS 82% Black and Asian ethnicity); prostate cancer (66% S1/2 Mixed/Other VS 65% Black VS 54% White ethnicity); uterine cancer (78% S1/2 White vs 66% Black ethnicity); lung (43% Black VS 40% White VS 30% Unknown ethnicity); and colorectal cancer (49% White VS 38% Black ethnicity).

Year	Month	Cancer group	Metric	Breakdown	Demographic	Data completeness	Numerator (12m)	Denominator (12m)	Statistic (12m)	Difference from proportion in White ethnicity
2024	October	All sites combined	Early stage proportion	Ethnicity	Asian	Complete	3861	6480	59.6	-1.3
2024	October	All sites combined	Early stage proportion	Ethnicity	Black	Complete	3412	5703	59.8	-1.5
2024	October	All sites combined	Early stage proportion	Ethnicity	Mixed and Other	Complete	3216	5237	61.4	-3.1
2024	October	All sites combined	Early stage proportion	Ethnicity	Unknown	Complete	12589	20733	60.7	-2.4
2024	October	All sites combined	Early stage proportion	Ethnicity	White	Complete	103538	177528	58.3	
2024	October	Bladder	Early stage proportion	Ethnicity	Asian	Complete	95	114	83.3	-2.4
2024	October	Bladder	Early stage proportion	Ethnicity	Black	Complete	58	77	75.3	5.6
2024	October	Bladder	Early stage proportion	Ethnicity	Mixed and Other	Complete	105	128	82	-1.1
2024	October	Bladder	Early stage proportion	Ethnicity	Unknown	Complete	319	391	81.6	-0.7
2024	October	Bladder	Early stage proportion	Ethnicity	White	Complete	4172	5155	80.9	
2024	October	Breast	Early stage proportion	Ethnicity	Asian	Complete	1446	1782	81.1	5.1
2024	October	Breast	Early stage proportion	Ethnicity	Black	Complete	854	1088	78.5	7.7
2024	October	Breast	Early stage proportion	Ethnicity	Mixed and Other	Complete	966	1162	83.1	3.1
2024	October	Breast	Early stage proportion	Ethnicity	Unknown	Complete	3241	3783	85.7	0.5
2024	October	Breast	Early stage proportion	Ethnicity	White	Complete	25995	30159	86.2	
2024	October	Colorectal	Early stage proportion	Ethnicity	Asian	Complete	395	889	44.4	4.6
2024	October	Colorectal	Early stage proportion	Ethnicity	Black	Complete	231	602	38.4	10.6
2024	October	Colorectal	Early stage proportion	Ethnicity	Mixed and Other	Complete	305	647	47.1	1.9
2024	October	Colorectal	Early stage proportion	Ethnicity	Unknown	Complete	1429	2962	48.2	0.8
2024	October	Colorectal	Early stage proportion	Ethnicity	White	Complete	12446	25409	49	
2024	October	Gynaecological	Early stage proportion	Ethnicity	Asian	Complete	461	650	70.9	-4.9
2024	October	Gynaecological	Early stage proportion	Ethnicity	Black	Complete	193	305	63.3	2.7
2024	October	Gynaecological	Early stage proportion	Ethnicity	Mixed and Other	Complete	239	362	66	0
2024	October	Gynaecological	Early stage proportion	Ethnicity	Unknown	Complete	749	1060	70.7	-4.7
2024	October	Gynaecological	Early stage proportion	Ethnicity	White	Complete	5457	8271	66	
2024	October	Haematological	Early stage proportion	Ethnicity	Asian	Complete	136	370	36.8	-2.8
2024	October	Haematological	Early stage proportion	Ethnicity	Black	Complete	55	139	39.6	-5.6
2024	October	Haematological	Early stage proportion	Ethnicity	Mixed and Other	Complete	84	232	36.2	-2.2
2024	October	Haematological	Early stage proportion	Ethnicity	Unknown	Complete	248	692	35.8	-1.8
2024	October	Haematological	Early stage proportion	Ethnicity	White	Complete	1816	5334	34	
2024	October	Hodgkin lymphoma	Early stage proportion	Ethnicity	Asian	Complete	41	88	46.6	1.1
2024	October	Hodgkin lymphoma	Early stage proportion	Ethnicity	Black	Complete	16	40	40	7.7
2024	October	Hodgkin lymphoma	Early stage proportion	Ethnicity	Mixed and Other	Complete	33	59	55.9	-8.2
2024	October	Hodgkin lymphoma	Early stage proportion	Ethnicity	Unknown	Complete	62	151	41.1	6.6
2024	October	Hodgkin lymphoma	Early stage proportion	Ethnicity	White	Complete	390	818	47.7	
2024	October	Kidney	Early stage proportion	Ethnicity	Asian	Complete	184	292	63	-4.2
2024	October	Kidney	Early stage proportion	Ethnicity	Black	Complete	113	166	68.1	-9.3
2024	October	Kidney	Early stage proportion	Ethnicity	Mixed and Other	Complete	151	244	61.9	-3.1
2024	October	Kidney	Early stage proportion	Ethnicity	Unknown	Complete	369	604	61.1	-2.3
2024	October	Kidney	Early stage proportion	Ethnicity	White	Complete	3704	6294	58.8	
2024	October	Lung	Early stage proportion	Ethnicity	Asian	Complete	293	750	39.1	1.4
2024	October	Lung	Early stage proportion	Ethnicity	Black	Complete	297	688	43.2	-2.7
2024	October	Lung	Early stage proportion	Ethnicity	Mixed and Other	Complete	319	768	41.5	-1
2024	October	Lung	Early stage proportion	Ethnicity	Unknown	Complete	642	2153	29.8	10.7
2024	October	Lung	Early stage proportion	Ethnicity	White	Complete	12722	31438	40.5	
2024	October	Melanoma	Early stage proportion	Ethnicity	Asian	Complete	28	34	82.4	11.8
2024	October	Melanoma	Early stage proportion	Ethnicity	Black	Complete	23	28	82.1	12.1
2024	October	Melanoma	Early stage proportion	Ethnicity	Mixed and Other	Complete	176	194	90.7	3.5
2024	October	Melanoma	Early stage proportion	Ethnicity	Unknown	Complete	1629	1709	95.3	-1.1
2024	October	Melanoma	Early stage proportion	Ethnicity	White	Complete	12161	12909	94.2	
2024	October	Non-Hodgkin lymphoma	Early stage proportion	Ethnicity	Asian	Complete	86	265	32.5	-1.4
2024	October	Non-Hodgkin lymphoma	Early stage proportion	Ethnicity	Black	Complete	29	82	35.4	-4.3
2024	October	Non-Hodgkin lymphoma	Early stage proportion	Ethnicity	Mixed and Other	Complete	45	154	29.2	1.9
2024	October	Non-Hodgkin lymphoma	Early stage proportion	Ethnicity	Unknown	Complete	170	506	33.6	-2.5
2024	October	Non-Hodgkin lymphoma	Early stage proportion	Ethnicity	White	Complete	1321	4245	31.1	
2024	October	Oesophageal	Early stage proportion	Ethnicity	Asian	Complete	33	121	27.3	3.3
2024	October	Oesophageal	Early stage proportion	Ethnicity	Black	Complete	15	71	21.1	9.5
2024	October	Oesophageal	Early stage proportion	Ethnicity	Mixed and Other	Complete	17	77	22.1	8.5
2024	October	Oesophageal	Early stage proportion	Ethnicity	Unknown	Complete	106	482	22	8.6
2024	October	Oesophageal	Early stage proportion	Ethnicity	White	Complete	1883	6145	30.6	
2024	October	Oesophago-gastric	Early stage proportion	Ethnicity	Asian	Complete	87	245	35.5	-4.3
2024	October	Oesophago-gastric	Early stage proportion	Ethnicity	Black	Complete	58	180	32.2	-1
2024	October	Oesophago-gastric	Early stage proportion	Ethnicity	Mixed and Other	Complete	45	171	26.3	4.9
2024	October	Oesophago-gastric	Early stage proportion	Ethnicity	Unknown	Complete	145	647	22.4	8.8
2024	October	Oesophago-gastric	Early stage proportion	Ethnicity	White	Complete	2564	8207	31.2	
2024	October	Ovarian	Early stage proportion	Ethnicity	Asian	Complete	102	202	50.5	-8.1
2024	October	Ovarian	Early stage proportion	Ethnicity	Black	Complete	52	92	56.5	-14.1
2024	October	Ovarian	Early stage proportion	Ethnicity	Mixed and Other	Complete	55	123	44.7	-2.3
2024	October	Ovarian	Early stage proportion	Ethnicity	Unknown	Complete	148	317	46.7	-4.3
2024	October	Ovarian	Early stage proportion	Ethnicity	White	Complete	1173	2767	42.4	
2024	October	Pancreatic	Early stage proportion	Ethnicity	Asian	Complete	60	211	28.4	-0.9
2024	October	Pancreatic	Early stage proportion	Ethnicity	Black	Complete	35	138	25.4	2.1
2024	October	Pancreatic	Early stage proportion	Ethnicity	Mixed and Other	Complete	42	143	29.4	-1.9
2024	October	Pancreatic	Early stage proportion	Ethnicity	Unknown	Complete	103	427	24.1	3.4
2024	October	Pancreatic	Early stage proportion	Ethnicity	White	Complete	1401	5099	27.5	
2024	October	Prostate	Early stage proportion	Ethnicity	Asian	Complete	676	1143	59.1	-5.3
2024	October	Prostate	Early stage proportion	Ethnicity	Black	Complete	1495	2292	65.2	-11.4
2024	October	Prostate	Early stage proportion	Ethnicity	Mixed and Other	Complete	784	1186	66.1	-12.3
2024	October	Prostate	Early stage proportion	Ethnicity	Unknown	Complete	3715	6305	58.9	-5.1
2024	October	Prostate	Early stage proportion	Ethnicity	White	Complete	21100	39253	53.8	
2024	October	Stomach	Early stage proportion	Ethnicity	Asian	Complete	54	124	43.5	-10.5
2024	October	Stomach	Early stage proportion	Ethnicity	Black	Complete	43	109	39.4	-6.4
2024	October	Stomach	Early stage proportion	Ethnicity	Mixed and Other	Complete	28	94	29.8	3.2
2024	October	Stomach	Early stage proportion	Ethnicity	Unknown	Complete	39	165	23.6	9.4
2024	October	Stomach	Early stage proportion	Ethnicity	White	Complete	681	2062	33	
2024	October	Upper GI excl OG	Early stage proportion	Ethnicity	Asian	Complete	60	211	28.4	-0.9
2024	October	Upper GI excl OG	Early stage proportion	Ethnicity	Black	Complete	35	138	25.4	2.1
2024	October	Upper GI excl OG	Early stage proportion	Ethnicity	Mixed and Other	Complete	42	143	29.4	-1.9
2024	October	Upper GI excl OG	Early stage proportion	Ethnicity	Unknown	Complete	103	427	24.1	3.4
2024	October	Upper GI excl OG	Early stage proportion	Ethnicity	White	Complete	1401	5099	27.5	
2024	October	Urological excl prostate	Early stage proportion	Ethnicity	Asian	Complete	279	406	68.7	0.1
2024	October	Urological excl prostate	Early stage proportion	Ethnicity	Black	Complete	171	243	70.4	-1.6
2024	October	Urological excl prostate	Early stage proportion	Ethnicity	Mixed and Other	Complete	256	372	68.8	0
2024	October	Urological excl prostate	Early stage proportion	Ethnicity	Unknown	Complete	688	995	69.1	-0.3
2024	October	Urological excl prostate	Early stage proportion	Ethnicity	White	Complete	7876	11449	68.8	
2024	October	Uterine	Early stage proportion	Ethnicity	Asian	Complete	359	448	80.1	-2.3
2024	October	Uterine	Early stage proportion	Ethnicity	Black	Complete	141	213	66.2	11.6
2024	October	Uterine	Early stage proportion	Ethnicity	Mixed and Other	Complete	184	239	77	0.8
2024	October	Uterine	Early stage proportion	Ethnicity	Unknown	Complete	601	743	80.9	-3.1
2024	October	Uterine	Early stage proportion	Ethnicity	White	Complete	4284	5504	77.8	

Rapid cancer registration data: variations in proportion of cancers diagnosed at Stage 1 / 2, 12 months to October 2024: NATIONAL (England) by gender

Topline overview The table only shows cancer types for which data was available. Of the cancers with data showing early stage proportions, across all sites combined, a lower proportion of cancers are diagnosed at an early stage in males (52%) compared to females (66%). This pattern is observed across most cancer sites, with the largest differences in proportion of S1/2 diagnoses seen for **breast cancer** (9 percentage point difference), **lung cancer** (7 percentage point difference), **Hodgkin Lymphoma** (7 percentage point difference). However, the inverse pattern is true for **bladder cancers** (8 percentage point difference). Proportions are very similar for colorectal cancer (48.8% in males, 48.2% in females)

Year	Month	Cancer group	Metric	Breakdown	Demographic	Data completeness	Denominator		Statistic (12m)	Column1
							Numerator (12m)	(12m)		
2024	October	All sites combined	Early stage proportion	Gender	Female	Complete	66338	100226	66.2	
2024	October	All sites combined	Early stage proportion	Gender	Male	Complete	60278	115455	52.2	-14
2024	October	Bladder	Early stage proportion	Gender	Female	Complete	1150	1528	75.3	
2024	October	Bladder	Early stage proportion	Gender	Male	Complete	3599	4337	83	7.7
2024	October	Breast	Early stage proportion	Gender	Female	Complete	32275	37679	85.7	
2024	October	Breast	Early stage proportion	Gender	Male	Complete	227	295	76.9	-8.8
2024	October	Cervical	Early stage proportion	Gender	Female	Complete	0	0	NA	
2024	October	Colorectal	Early stage proportion	Gender	Female	Complete	6547	13590	48.2	
2024	October	Colorectal	Early stage proportion	Gender	Male	Complete	8259	16919	48.8	0.6
2024	October	Gynaecological	Early stage proportion	Gender	Female	Complete	7099	10648	66.7	
2024	October	Haematological	Early stage proportion	Gender	Female	Complete	1070	3010	35.5	
2024	October	Haematological	Early stage proportion	Gender	Male	Complete	1269	3757	33.8	-1.7
2024	October	Hodgkin lymphoma	Early stage proportion	Gender	Female	Complete	261	516	50.6	
2024	October	Hodgkin lymphoma	Early stage proportion	Gender	Male	Complete	281	640	43.9	-6.7
2024	October	Kidney	Early stage proportion	Gender	Female	Complete	1736	2823	61.5	
2024	October	Kidney	Early stage proportion	Gender	Male	Complete	2785	4777	58.3	-3.2
2024	October	Lung	Early stage proportion	Gender	Female	Complete	7809	18053	43.3	
2024	October	Lung	Early stage proportion	Gender	Male	Complete	6464	17744	36.4	-6.9
2024	October	Melanoma	Early stage proportion	Gender	Female	Complete	6937	7269	95.4	
2024	October	Melanoma	Early stage proportion	Gender	Male	Complete	7080	7605	93.1	-2.3
2024	October	Non-Hodgkin lymphoma	Early stage proportion	Gender	Female	Complete	734	2335	31.4	
2024	October	Non-Hodgkin lymphoma	Early stage proportion	Gender	Male	Complete	917	2917	31.4	0
2024	October	Oesophageal	Early stage proportion	Gender	Female	Complete	629	1910	32.9	
2024	October	Oesophageal	Early stage proportion	Gender	Male	Complete	1425	4986	28.6	-4.3
2024	October	Oesophago-gastric	Early stage proportion	Gender	Female	Complete	940	2812	33.4	
2024	October	Oesophago-gastric	Early stage proportion	Gender	Male	Complete	1959	6638	29.5	-3.9
2024	October	Ovarian	Early stage proportion	Gender	Female	Complete	1530	3501	43.7	
2024	October	Pancreatic	Early stage proportion	Gender	Female	Complete	775	2814	27.5	
2024	October	Pancreatic	Early stage proportion	Gender	Male	Complete	866	3204	27	-0.5
2024	October	Prostate	Early stage proportion	Gender	Male	Complete	27770	50179	55.3	
2024	October	Stomach	Early stage proportion	Gender	Female	Complete	311	902	34.5	
2024	October	Stomach	Early stage proportion	Gender	Male	Complete	534	1652	32.3	-2.2
2024	October	Upper GI excl OG	Early stage proportion	Gender	Female	Complete	775	2814	27.5	
2024	October	Upper GI excl OG	Early stage proportion	Gender	Male	Complete	866	3204	27	-0.5
2024	October	Urological excl prostate	Early stage proportion	Gender	Female	Complete	2886	4351	66.3	
2024	October	Urological excl prostate	Early stage proportion	Gender	Male	Complete	6384	9114	70	3.7
2024	October	Uterine	Early stage proportion	Gender	Female	Complete	5569	7147	77.9	

Rapid cancer registration data – early stage proportions comparator F, SH, national (12 month to Feb 24)

Geog	Geography	Cancer group	Metric	Statistic (12m)	Geography	Statistic (12m)	Geography	Statistic (12m)
ICB	NHS Surrey Heartlands Integr:	All sites combined	Early stage proportion	64.7	NHS Frimley Integrated Care	61.4	England	58.3
ICB	NHS Surrey Heartlands Integr:	Bladder	Early stage proportion	87.9	NHS Frimley Integrated Care	86.8	England	80.7
ICB	NHS Surrey Heartlands Integr:	Brain and CNS	Early stage proportion	NA	NHS Frimley Integrated Care	NA	England	NA
ICB	NHS Surrey Heartlands Integr:	Breast	Early stage proportion	87.7	NHS Frimley Integrated Care	80.7	England	85.2
ICB	NHS Surrey Heartlands Integr:	Colorectal	Early stage proportion	51	NHS Frimley Integrated Care	56.7	England	48.8
ICB	NHS Surrey Heartlands Integr:	Gynaecological	Early stage proportion	70.4	NHS Frimley Integrated Care	71.5	England	65.5
ICB	NHS Surrey Heartlands Integr:	Haematological	Early stage proportion	43.9	NHS Frimley Integrated Care	42.9	England	34.5
ICB	NHS Surrey Heartlands Integr:	Head and Neck	Early stage proportion	NA	NHS Frimley Integrated Care	NA	England	NA
ICB	NHS Surrey Heartlands Integr:	Kidney	Early stage proportion	60	NHS Frimley Integrated Care	66.4	England	59.9
ICB	NHS Surrey Heartlands Integr:	Lip, oral cavity and pharynx	Early stage proportion	NA	NHS Frimley Integrated Care	NA	England	NA
ICB	NHS Surrey Heartlands Integr:	Liver	Early stage proportion	NA	NHS Frimley Integrated Care	NA	England	NA
ICB	NHS Surrey Heartlands Integr:	Lung	Early stage proportion	34.3	NHS Frimley Integrated Care	36.9	England	37.5
ICB	NHS Surrey Heartlands Integr:	Melanoma	Early stage proportion	95.6	NHS Frimley Integrated Care	96.6	England	94.4
ICB	NHS Surrey Heartlands Integr:	Multiple myeloma	Early stage proportion	NA	NHS Frimley Integrated Care	NA	England	NA
ICB	NHS Surrey Heartlands Integr:	Non-Hodgkin lymphoma	Early stage proportion	45.1	NHS Frimley Integrated Care	45.5	England	31.4
ICB	NHS Surrey Heartlands Integr:	Oesophageal	Early stage proportion	31.3	NHS Frimley Integrated Care	29.2	England	30.2
ICB	NHS Surrey Heartlands Integr:	Oesophago-gastric	Early stage proportion	36.1	NHS Frimley Integrated Care	29.5	England	30.6
ICB	NHS Surrey Heartlands Integr:	Ovarian	Early stage proportion	36.2	NHS Frimley Integrated Care	43.2	England	40.2
ICB	NHS Surrey Heartlands Integr:	Pancreatic	Early stage proportion	35.1	NHS Frimley Integrated Care	30.1	England	28.4
ICB	NHS Surrey Heartlands Integr:	Prostate	Early stage proportion	69	NHS Frimley Integrated Care	52.9	England	54.8
ICB	NHS Surrey Heartlands Integr:	Unknown	Early stage proportion	NA	NHS Frimley Integrated Care	NA	England	NA
ICB	NHS Surrey Heartlands Integr:	Upper GI excl OG	Early stage proportion	35.1	NHS Frimley Integrated Care	30.1	England	28.4
ICB	NHS Surrey Heartlands Integr:	Urological excl prostate	Early stage proportion	72.6	NHS Frimley Integrated Care	73.5	England	69.3
ICB	NHS Surrey Heartlands Integr:	Uterine	Early stage proportion	84.8	NHS Frimley Integrated Care	81.3	England	78.3

Topline NDRS stage at diagnosis by cancer type – comparing SH, F and national

- >75% diagnosed at early stage all geographies: Bladder, Breast, Melanoma, Uterine; higher in SH compared to national for all of these; higher for F for bladder, melanoma. Uterine; lower for F than national for breast
- Between 50 – 75% at early stage for colorectal, gynaecological, kidney, prostate, urological (exc. Prostate) for all geographies, except colorectal which is <50% nationally/
 - SH colorectal, gynaecological, kidney and urological (exc. Prostate) lower than F, but higher nationally
 - F prostate lower than both SH and nationally
- <50% diagnosed at early stage for haematological, lung, NHL, oesophageal, oesophago-gastric, ovarian, pancreatic, upper GI exc, OG in all geographics (+ colorectal nationally)
 - Lowest rates in SH (<35%) for:
 - lung – lower in SH (34.4) than F (36.9), and lower in both than nationally (37.5)
 - Oesophageal – higher in SH (31) than F (29) and nationally (30)
 - Lowest rates in F (<35%) for:
 - Oesophageal (29) and oesophago-gastric (30)
 - Pancreatic (30) – lower than SH (35) but higher than national (28)
 - Upper GI exc OG – lower than SH (35) but higher than national (28)

About the data source

National Disease Registration Service

The information below is copied directly from the database above. For full information see nhsd-ndrs.shinyapps.io/staging_data_in_england/

Introduction

Early stage at diagnosis is one of the most important factors affecting cancer outcomes, and promoting earlier stage at diagnosis is one of the key aims of the NHS Long-Term plan. Measuring and monitoring national staging data is crucial to understand variation and deliver evidence-based decisions. This tool contains information on staging data in England, as collected and compiled by the National Disease Registration Service (NDRS). The following staging data is included:

75% ambition: Percentage of stageable cancers diagnosed at stage 1 and 2 in England, by Cancer Alliance

Case-mix adjusted: Percentage of cancers diagnosed at stage 1 and 2 in England, by sub-Integrated Care Board location (sub-ICBL)

Cancer site: Stage group by sub-ICBL, Integrated Care Board (ICB) or Cancer Alliance, by cancer type for 21 cancer types

Deprivation: Stage group by deprivation by cancer type for 21 cancer types

Completeness: registration and stage, 2013-2021

The tool uses the most recently available data taken from the Cancer Analysis System CAS2309 data snapshot, and subsequent updates may retrospectively change the values for the current release. This is because cancer registration is an ongoing process. This release uses the Cancer Alliance list from 2023. The geographies include 106 sub-ICBLs, 21 Cancer Alliances and 42 ICBs. This will be updated in future release to reflect changes to these geographies. For cancers diagnosed between 2012 and 2013, the 2015 release of the English indices of deprivation is applied. For cancers diagnosed since 2014, the 2019 release is applied.

Acknowledgement: This work uses data that has been provided by patients and collected by the NHS as part of their care and support. The data are collated, maintained and quality assured by the National Disease Registration Service, which is part of NHS England.

Methods

Percentage of stageable cancers diagnosed at stage 1 and 2 in England, by Cancer Alliance: The percentage of stageable cancers diagnosed at stages 1 and 2 in England indicated is presented at Cancer Alliance level as a 1-year rolling percentage (which combines the most recent year of data) for calendar years 2013-2021. This indicator is intended to measure progress towards the ambition that 75% of all stageable cancers will be diagnosed as stage 1 and 2 by 2028

Numerator: Cases of cancer diagnosed at stages 1 & 2 for the cancer sites as defined in "Included site groups" and "Included morphological groups"

Denominator: Cases of cancer diagnosed at any known stage (stage 1 & 2, stage 3 & 4) for cancer sites as defined in "Included site groups" and "Included morphological groups"

One year rolling percentage: New cases of cancer diagnosed at stages 1 & 2 is calculated as a percentage of all new cases of cancer diagnosed at any known stage (stage 1 & 2, stage 3 & 4). The 1-year rolling proportion for a stated quarter includes the previous 3 quarters' worth of data meaning a full 12 months of data is used. The denominator is then the total number of cancer presentations for those 4 quarters and the numerator is the total emergency presentations for those 4 quarters.


Confidence Intervals Confidence intervals were calculated using the Wilson Score method, described in detail in APHO technical briefing 3

Other info:


The percentages here are not case-mix adjusted and do not account for differences between Cancer Alliance populations. The case-mix of cancers diagnosed impacts on the percentage of early stage cancers. For example, breast cancer is far more likely to be diagnosed at stage 1 and 2 than lung cancer. Therefore, alliances with a higher than average occurrence of breast cancer tend to have a higher percentage of early stage cancers compared to alliances with a higher than average occurrence of lung cancer.

Data are checked at each stage of processing. The initial code to derive and extract data is established and tested, with any changes quality assured by an analyst familiar with the coding system. The output is checked for completeness by assessing missing fields and comparing numbers to previous publications of the data. For areas where staging completeness is still low, this indicator may not reflect the true percentage of cases of cancer at stage 1 and 2.

Percentage of cancers staged by cancer site (2021) in NHS Surrey Heartlands ICB and NHS Frimley ICB







This work has been produced by The National Disease Registration Service.



This work has been produced by The National Disease Registration Service.


Comparisons to SSCA and England on the following slide

Percentage of cancers staged by cancer site (2021) in NHS Surrey Heartlands ICB and NHS Frimley ICB



Stage at diagnosis – by Cancer Alliance compared to England and 75% ambition (2013-2021)

Yearly rolling percentage of cancers diagnosed at stage 1 and 2 in Surrey and Sussex and England, 2013-2021



Topline NDRS stage at diagnosis

- Surrey and Sussex CA consistently ahead of all England (Q4 2021 54.3%) in proportion of cancers diagnosed at S1/2 but latest data (Q4 2021 55.6%) shows a 20% shortfall of the NHS LTP 75% S1/2 by 2029 ambition
- The 2021 Case Mix Adjusted S1/2 % is:
 - 52.8% in Frimley ICB (consistently slightly lower than 54.5% all England and consistently lower since 2013)
 - 55.5% in Surrey Heartlands ICB (marginally higher than England and consistently equivalent or higher since 2013)

Stage at diagnosis – by site (national) - 2021

Differences in staging by cancer type

Site	%S1/2: 1 - Most deprived	%S1/2: 2	%S1/2:3	%S1/2:4	%S1/2:5 - Least deprived	Gap: Least - most deprived
Oropharynx, base of tongue, tonsil, soft palate and uvula	44.88	51.69	56.78	56.28	56.37	11.49
Oral cavity, hard palate and lip (inner aspect)	38.71	36.01	40.21	41.17	48.84	10.13
All sites	49.00	52.18	54.19	55.54	56.67	7.68
Larynx including anterior surface of epiglottis	48.30	52.99	57.59	50.00	55.71	7.41
Prostate	47.27	49.12	49.46	50.78	52.46	5.19
Breast	81.63	83.99	85.61	85.76	86.17	4.54
Rectum and rectosigmoid junction	39.10	42.02	44.24	45.32	43.00	3.90
Colon	44.65	48.08	47.51	48.05	48.28	3.63
Oesophagus including cardia and gastroesophageal junction	17.19	18.60	20.49	20.09	20.65	3.46
Melanoma of skin	84.79	84.28	86.50	87.54	87.80	3.01
Bladder	70.65	71.57	73.71	73.84	72.74	2.09
Non-Hodgkin lymphoma	26.35	28.00	27.43	27.04	28.02	1.67
Other	45.70	45.73	47.50	49.58	47.34	1.64
Testis	88.68	91.48	93.00	89.16	89.59	0.91
Pancreas	24.39	25.06	24.27	26.44	25.21	0.82
Uterus	77.74	78.09	79.81	78.61	78.54	0.80
Lung	31.24	30.35	30.80	31.30	31.88	0.64
Hodgkin lymphoma	43.30	50.16	45.94	45.34	41.29	-2.01
Kidney, except renal pelvis	59.79	56.49	57.93	55.51	57.37	-2.42
Ovary, fallopian tube and primary peritoneal carcinomas	43.02	42.44	37.57	34.04	35.55	-7.47

Less than 30% S1/2

Less than 40% S1/2

Less than 50% S1/2

Topline NDRS stage at diagnosis by 19 cancer type

- Data only available at national level
- Data only includes 19 cancer sites*
- Biggest deprivation gap in proportion of cancer cases diagnosed at early stage (S1/2) exists in cancers of the **head and neck**: oropharyngeal cancers (11.49%), oral cavity cancers (10.13%) and laryngeal (7.41%)
- The inverse is true of **ovarian** (-7.47%), **kidney** (-2.42%) and **Hodgkin lymphoma** (-2.01%) cancers, a lower proportion of which are cases diagnosed at an early stage (S1/2)
- But as shown on the next slide, **<75% cancers** were staged for the following cancer sites:
 - SH: prostate, ovarian, kidney, bladder, breast, NHL, HL, pancreatic and other cancers
 - Frimley: ovarian, kidney, NHL, pancreatic and other cancers
 - Surrey & Sussex CA: uterus, kidney, bladder, NHL, ovarian, pancreatic and other cancers
 - kidney, bladder, NHL, ovarian, pancreatic and other cancers

*Bladder; Breast; Colon; Hodgkin lymphoma; Kidney, except renal pelvis; Larynx including anterior surface of epiglottis; Lung; Melanoma of skin; Non-Hodgkin lymphoma; Oesophagus including cardia and gastroesophageal junction; Oral cavity, hard palate and lip (inner aspect); Oropharynx, base of tongue, tonsil, soft palate and uvula; Other; Ovary, fallopian tube and primary peritoneal carcinomas; Pancreas; Prostate; Rectum and rectosigmoid junction; Testis; Uterus

Percentage cancers diagnosed at Stages 1 or 2 (2021)

Source: [OHID Fingertips Cancer Services](#)

By Surrey District and Borough

Indicator
Percentage of cancers diagnosed at stages 1 and 2
2021 Proportion - %

[Show me the profiles these indicators are from](#)

[Legend](#) [Benchmark](#) [More options](#)

Geography version Districts & UAs (from Apr 2023)

[Show 99.8% CI values](#)

Area	Value
England	54.4
Surrey	57.6
Surrey Heath	61.7
Mole Valley	60.1
Woking	59.5
Guildford	59.2
Elmbridge	59.2
Runnymede	59.1
Spelthorne	58.5
Reigate and Banstead	55.3
Tandridge	54.7
Waverley	53.2
Epsom and Ewell	*

Source: NHS England, National Disease Registration Service

By deprivation (national level data only)


Indicator
Percentage of cancers diagnosed at stages 1 and 2 Proportion - %

[Show me the profiles these indicators are from](#)

[Legend](#) [Benchmark](#) [More options](#)

Display [Single time period](#) [Trends](#) [Inequalities for England](#) [Hide confidence intervals](#) [Show 99.8% CI values](#)

2013 2014 2015 2016 2017 2018 2019 2020 **2021**



	Count	Value	95% Lower CI	95% Upper CI
England	119,781	54.4	54.2	54.6
Most deprived decile (IMD2019)	14,359	52.3	51.7	52.9
Second most deprived decile (IMD2019)	15,583	52.9	52.3	53.5
Third more deprived decile (IMD2019)	13,269	53.6	53.0	54.2
Fourth more deprived decile (IMD2019)	11,524	53.4	52.8	54.1
Fifth more deprived decile (IMD2019)	10,359	54.3	53.6	55.0
Fifth less deprived decile (IMD2019)	13,373	55.6	55.0	56.3
Fourth less deprived decile (IMD2019)	12,728	55.4	54.8	56.1
Third less deprived decile (IMD2019)	9,870	55.4	54.7	56.1
Second least deprived decile (IMD2019)	9,316	55.7	54.9	56.4
Least deprived decile (IMD2019)	9,400	57.9	57.2	58.7

Routes to diagnosis

The proportion of cancers diagnosed at an early stage, and net survival, are higher for those diagnosed through managed routes compared to emergency presentations.

About the data source

National Disease Registration Service [Routes to Diagnosis](#) dashboard

The information below is copied directly from the database above. For full information see [Routes to Diagnosis](#)

Introduction This tool contains information on Routes to Diagnosis, a method of identifying and categorising key events that lead to a patient's diagnosis of cancer. Compared to the European average, cancer survival in England is low. Studies suggested this difference could largely be due to later diagnosis, when cancers have progressed to a more advanced stage and are harder to treat. In 2012 a study was published in an attempt to shed more light on patients' journeys to diagnosis to see what could be improved. This was the award-winning Routes to Diagnosis study, which defined a methodology to determine the route a patient took through the healthcare system before receiving a cancer diagnosis. Routes to diagnosis found large differences in how patients were diagnosed and large variation in survival between these groups. In particular it was found that one in four cancer patients were diagnosed as an emergency presentation, and that this route was associated with low survival. This release contains data for patients diagnosed from 2006 to 2020 and are presented for England. Results for Emergency Presentations are also presented by NHS Region, Integrated Care Board (ICB) and sub-ICB Locations (SICBL).

Methods: Administrative Hospital Episode Statistics (HES) data are combined with Cancer Waiting Times (CWT) data, data from national cancer screening programmes and national cancer registration data. Using these datasets, every case of cancer registered in England diagnosed between 2006 and 2020 is categorised into one of eight 'Routes to Diagnosis' listed below. The full methodology is described in the British Journal of Cancer article, Routes to Diagnosis for cancer - Determining the patient journey using multiple routine datasets, which was published in October 2012.

Incidence

Longer time trend data (2006 to 2020) is presented for the below cancer sites, by year, for England only. The cancer sites are defined by ICD-10 code and align with the coding used for National Statistics.

- All malignant neoplasms excluding NMSC Breast (females only) Colorectal Lung Prostate

The data displayed in the Demographics, Stage and Emergency Presentations tabs are defined using a different coding system, a combination of ICD-10 and ICD-O-3. This data is presented for 2013 to 2020.

Demographics: Count and percentage of cancers diagnosed each year split by Route. Data can be further broken down by cancer site and demographic factor (age, deprivation quintile, gender and ethnicity). Age is defined as the broad age group at diagnosis (0-49, 50-59, 60-69, 70-79, 80-84, 85+). The deprivation quintile refers to the socio-economic deprivation quintile (1 - most deprived to 5 - least deprived) from the English indices of deprivation, based on area of residence at diagnosis. The index with the closest match between diagnosis year and the year of the underlying deprivation population is used. 2007 indices are used for patients diagnosed in 2006. 2010 indices for patients diagnosed between 2007 and 2009. 2015 indices for patients diagnosed between 2010 and 2013. 2019 indices for patients diagnosed from 2014 onwards. Gender is stated gender not gender assigned at birth. Broad ethnic groups are aligned with the census (Asian excluding Chinese, Black, Chinese, Mixed, White, Other ethnicity and Unknown ethnicity).

Stage: Count and percentage of TNM stage at diagnosis split by Route. Data are broken down by select cancer sites (see table) and can be presented to show Stage by Route or Route by Stage.

Emergency Presentations: Count and percentage of cancers diagnosed each year split by Emergency Presentation Route. Data can be broken down by cancer site. For percentages, the denominator can be changed to present All Routes or Emergency Presentation Routes only.

Confidence intervals: Binomial confidence intervals for proportions are calculated using the Wilson score method

Route	Definition
GP referral	Routine and urgent referrals where the patient was not referred under the USC referral route
Urgent Suspected Cancer (USC)	Urgent GP referrals with a suspicion of cancer (previously known as Two-week wait/TWW)
Emergency presentation	An emergency route via accident and emergency (A&E), emergency GP referral, emergency transfer, emergency admission or attendance
Other outpatient	An elective route starting with an outpatient appointment that is either a self-referral, consultant to consultant referral, other or unknown referral (excludes patients originally referred under the USC referral route)
Screen-detected	Flagged by the cancer registry as detected via the breast, bowel or cervical screening programmes
Inpatient elective	No earlier information can be found prior to admission from a waiting list, booked or planned
DCO	Diagnosis by death certificate only
Unknown route	No relevant data available from Inpatient or Outpatient HES, National Cancer Waiting Times or National Screening Programmes

Routes to diagnosis: topline takehomes

Topline insights - In FH vs SH v England – on 5 reported cancers (2013 – 2020) from NDRS


- Similar to England, of the 5 selected cancers, **lung cancers (small cell and non-small cell) have the highest proportion of emergency presentation with only around ~60 -70% diagnosed via non-emergency routes**, and up to 40% being diagnosed via A&E emergency presentation (comparatively slightly higher than SH (~25 – 35%) and England (~25%)
- **Compared to England, a similar proportion of colorectal cancers are diagnosed via emergency routes (similar to SH) (~20 - 25%)**
- Similar to England, >90% breast and prostate cancers in FH and SH are diagnosed by non-emergency routes
- Generally, a slightly higher proportion of all malignant neoplasms in FH and SH (80-84%) are diagnosed via non-emergency routes than England (77 – 81%). In 2020 (most recent complete data available): 78% in England VS 80% in both Surrey Heartlands and Frimley

Fingertips Cancer services key indicators - in England, SH and F ICBs


- No trend information for urgent suspected cancer referrals, but rate higher in SH (101.3) than England, and lower in Frimley (82.8) than England
- % of USCRs resulting cancer diagnosis has increased from 2018/19 to 2022/23 – no trend info for SH or Frimley, but higher in both (6.8 and 6.9) than England (6.6)
- % new cancer cases treated after USCR has increased from 2018/2019 to 2022/2023 – no trend info for SH or Frimley but higher in SH (55.4) and lower in Frimley (48.2) than England (54.1)

Routes to diagnosis – National (2013-2020): visual representation over time (data on following slide)


All malignant neoplasms




Breast




Colorectal




Lung non-small cell



Lung – small-cell



Prostate



Routes to diagnosis – national

**Only cancer sites data available for SH and FH:
All malignant neoplasms; breast; colorectal; lung – NSC; lung – SC; prostate
2013 - 2020**

Topline take-homes - in England:


- Of the 5 selected cancers, **lung cancers (small cell and non-small cell) have the highest proportion of emergency presentation** with ~25% cases diagnosed via A&E emergency presentation, and only around ~60-70% diagnosed via non-emergency routes from 2015 - 2020
- **~25% colorectal cancers are diagnosed via emergency routes**, ~15-20% is within A&E
- >90% breast and prostate cancers diagnosed by non-emergency routes
- 77-80% all malignant neoplasms diagnosed via non-emergency routes

Site	Year	Area	Geography	A and E (%)	GP EP (%)	Other EP (%)	All other routes (%)
All Malignant Neoplasms (excl. NMSC)	2013	Country	England	13.7	3.9	3.1	79.3
All Malignant Neoplasms (excl. NMSC)	2014	Country	England	13.4	3.6	3.1	79.9
All Malignant Neoplasms (excl. NMSC)	2015	Country	England	13.3	3.4	3.1	80.2
All Malignant Neoplasms (excl. NMSC)	2016	Country	England	13.6	3.0	3.0	80.4
All Malignant Neoplasms (excl. NMSC)	2017	Country	England	13.4	2.7	3.0	80.9
All Malignant Neoplasms (excl. NMSC)	2018	Country	England	13.1	2.5	2.9	81.4
All Malignant Neoplasms (excl. NMSC)	2019	Country	England	13.8	2.4	3.2	80.6
All Malignant Neoplasms (excl. NMSC)	2020	Country	England	16.5	2.4	3.6	77.5
Breast	2013	Country	England	2.8	0.6	0.6	96.0
Breast	2014	Country	England	2.8	0.6	0.5	96.1
Breast	2015	Country	England	2.8	0.5	0.6	96.2
Breast	2016	Country	England	2.6	0.5	0.6	96.3
Breast	2017	Country	England	2.8	0.4	0.5	96.2
Breast	2018	Country	England	2.7	0.4	0.5	96.4
Breast	2019	Country	England	3.0	0.5	0.6	95.9
Breast	2020	Country	England	3.6	0.5	0.7	95.2


Site	Year	Area	Geography	A and E (%)	GP EP (%)	Other EP (%)	routes (%)
Colorectal	2013	Country	England	16.7	5.3	2.5	75.5
Colorectal	2014	Country	England	16.2	5.0	2.6	76.2
Colorectal	2015	Country	England	16.3	4.6	2.6	76.5
Colorectal	2016	Country	England	16.3	4.2	2.5	77.1
Colorectal	2017	Country	England	15.6	3.6	2.6	78.2
Colorectal	2018	Country	England	16.3	3.5	2.5	77.6
Colorectal	2019	Country	England	16.0	3.0	2.7	78.3
Colorectal	2020	Country	England	18.4	3.0	3.1	75.6
Lung - non-small cell	2013	Country	England	25.2	5.5	4.3	65.0
Lung - non-small cell	2014	Country	England	24.8	5.1	4.6	65.5
Lung - non-small cell	2015	Country	England	24.5	4.6	4.4	66.5
Lung - non-small cell	2016	Country	England	24.2	3.9	4.3	67.6
Lung - non-small cell	2017	Country	England	24.1	3.5	4.1	68.3
Lung - non-small cell	2018	Country	England	24.2	3.3	4.3	68.2
Lung - non-small cell	2019	Country	England	24.6	3.1	4.7	67.5
Lung - non-small cell	2020	Country	England	28.9	2.7	5.1	63.3
Lung - small cell	2013	Country	England	24.4	6.6	4.6	64.4
Lung - small cell	2014	Country	England	23.3	5.5	4.6	66.6
Lung - small cell	2015	Country	England	22.8	5.5	4.9	66.8
Lung - small cell	2016	Country	England	22.7	4.8	4.5	68.0
Lung - small cell	2017	Country	England	24.0	4.0	4.4	67.6
Lung - small cell	2018	Country	England	24.8	4.6	4.7	65.8
Lung - small cell	2019	Country	England	23.9	3.8	5.2	67.1
Lung - small cell	2020	Country	England	27.0	4.2	5.1	63.8
Prostate	2013	Country	England	6.0	1.2	1.6	91.2
Prostate	2014	Country	England	5.1	1.1	1.5	92.3
Prostate	2015	Country	England	5.3	1.0	1.5	92.2
Prostate	2016	Country	England	5.3	0.9	1.5	92.3
Prostate	2017	Country	England	4.9	0.8	1.5	92.7
Prostate	2018	Country	England	4.3	0.7	1.3	93.7
Prostate	2019	Country	England	4.9	0.8	1.5	92.7
Prostate	2020	Country	England	6.4	0.9	1.9	90.9

Routes to diagnosis – NHS Surrey Heartlands ICB (2013-2020): visual representation over time (data on following slide)


All malignant neoplasms




Breast




Colorectal




Lung non-small cell



Lung – small-cell



Prostate



Routes to diagnosis – sub ICB level - SH

Only cancer sites data available for for SH and FH:
All malignant neoplasms; breast; colorectal; lung – NSC; lung – SC; prostate 2013 - 2020

Topline takehomes - In SH v England


- Similar to England, of the 5 selected cancers, **lung cancers (small cell and non-small cell) have the highest proportion of emergency presentation** with only around ~65 - 75% diagnosed via non-emergency routes, and up to 35% being diagnosed via A&E emergency presentation
- Compared to England, a similar, but slightly relatively higher proportion of colorectal cancers are diagnosed via non-emergency routes (~21%)
- Similar to England, >90% breast and prostate cancers diagnosed by non-emergency routes
- Outperforming England, 80-84% all malignant neoplasms diagnosed via non-emergency routes

Site	Year	Area	Geography	A and E (%)	GP EP (%)	Other EP (%)	All other routes (%)
All Malignant Neoplasms (excl. NMSC)	2013	SICBL	NHS Surrey Heartlands ICB - 92A	14.8	2.0	3.0	80.1
All Malignant Neoplasms (excl. NMSC)	2014	SICBL	NHS Surrey Heartlands ICB - 92A	14.7	1.9	2.3	81.1
All Malignant Neoplasms (excl. NMSC)	2015	SICBL	NHS Surrey Heartlands ICB - 92A	14.6	1.1	2.4	82.0
All Malignant Neoplasms (excl. NMSC)	2016	SICBL	NHS Surrey Heartlands ICB - 92A	14.2	0.9	2.7	82.2
All Malignant Neoplasms (excl. NMSC)	2017	SICBL	NHS Surrey Heartlands ICB - 92A	13.8	1.3	2.2	82.7
All Malignant Neoplasms (excl. NMSC)	2018	SICBL	NHS Surrey Heartlands ICB - 92A	12.9	0.6	2.3	84.2
All Malignant Neoplasms (excl. NMSC)	2019	SICBL	NHS Surrey Heartlands ICB - 92A	13.3	0.7	2.5	83.6
All Malignant Neoplasms (excl. NMSC)	2020	SICBL	NHS Surrey Heartlands ICB - 92A	16.3	0.6	3.1	80.0
Breast	2013	SICBL	NHS Surrey Heartlands ICB - 92A	3.1	0.6	0.5	95.8
Breast	2014	SICBL	NHS Surrey Heartlands ICB - 92A	2.4	0.4	0.7	96.5
Breast	2015	SICBL	NHS Surrey Heartlands ICB - 92A	2.1	0.1	0.5	97.3
Breast	2016	SICBL	NHS Surrey Heartlands ICB - 92A	2.1	0.2	0.7	97.0
Breast	2017	SICBL	NHS Surrey Heartlands ICB - 92A	2.4	0.5	0.3	96.7
Breast	2018	SICBL	NHS Surrey Heartlands ICB - 92A	3.6	0.1	0.6	95.8
Breast	2019	SICBL	NHS Surrey Heartlands ICB - 92A	3.3	0.2	0.5	96.1
Breast	2020	SICBL	NHS Surrey Heartlands ICB - 92A	4.1	0.1	0.8	95.0


Colorectal	2013	SICBL	NHS Surrey Heartlands ICB - 92A	17.5	2.8	1.6	78.1
Colorectal	2014	SICBL	NHS Surrey Heartlands ICB - 92A	17.2	3.1	1.9	77.8
Colorectal	2015	SICBL	NHS Surrey Heartlands ICB - 92A	18.5	2.0	1.3	78.2
Colorectal	2016	SICBL	NHS Surrey Heartlands ICB - 92A	16.5	1.7	2.4	79.4
Colorectal	2017	SICBL	NHS Surrey Heartlands ICB - 92A	17.8	1.2	1.6	79.4
Colorectal	2018	SICBL	NHS Surrey Heartlands ICB - 92A	17.8	0.4	3.0	78.8
Colorectal	2019	SICBL	NHS Surrey Heartlands ICB - 92A	19.7	1.1	2.7	76.5
Colorectal	2020	SICBL	NHS Surrey Heartlands ICB - 92A	17.9	0.8	1.9	79.3
Lung - non-small cell	2013	SICBL	NHS Surrey Heartlands ICB - 92A	28.2	3.0	4.7	64.1
Lung - non-small cell	2014	SICBL	NHS Surrey Heartlands ICB - 92A	31.0	2.8	3.6	62.6
Lung - non-small cell	2015	SICBL	NHS Surrey Heartlands ICB - 92A	25.1	1.3	3.8	69.9
Lung - non-small cell	2016	SICBL	NHS Surrey Heartlands ICB - 92A	25.8	1.2	3.1	69.9
Lung - non-small cell	2017	SICBL	NHS Surrey Heartlands ICB - 92A	23.2	2.0	3.0	71.8
Lung - non-small cell	2018	SICBL	NHS Surrey Heartlands ICB - 92A	23.7	0.7	3.5	72.1
Lung - non-small cell	2019	SICBL	NHS Surrey Heartlands ICB - 92A	19.0	1.3	4.3	75.3
Lung - non-small cell	2020	SICBL	NHS Surrey Heartlands ICB - 92A	29.1	0.8	6.1	64.0
Lung - small cell	2013	SICBL	NHS Surrey Heartlands ICB - 92A	24.5	0.0	4.1	71.4
Lung - small cell	2014	SICBL	NHS Surrey Heartlands ICB - 92A	29.8	3.5	1.8	64.9
Lung - small cell	2015	SICBL	NHS Surrey Heartlands ICB - 92A	28.9	0.0	2.6	68.4
Lung - small cell	2016	SICBL	NHS Surrey Heartlands ICB - 92A	18.0	1.6	8.2	72.1
Lung - small cell	2017	SICBL	NHS Surrey Heartlands ICB - 92A	34.0	0.0	2.1	63.8
Lung - small cell	2018	SICBL	NHS Surrey Heartlands ICB - 92A	35.7	2.4	0.0	61.9
Lung - small cell	2019	SICBL	NHS Surrey Heartlands ICB - 92A	27.5	0.0	2.5	70.0
Lung - small cell	2020	SICBL	NHS Surrey Heartlands ICB - 92A	36.8	0.0	0.0	63.2
Prostate	2013	SICBL	NHS Surrey Heartlands ICB - 92A	8.9	1.0	2.1	88.0
Prostate	2014	SICBL	NHS Surrey Heartlands ICB - 92A	8.0	0.9	1.7	89.4
Prostate	2015	SICBL	NHS Surrey Heartlands ICB - 92A	8.6	0.1	1.1	90.2
Prostate	2016	SICBL	NHS Surrey Heartlands ICB - 92A	6.6	0.0	1.8	91.6
Prostate	2017	SICBL	NHS Surrey Heartlands ICB - 92A	5.3	0.4	0.7	93.5
Prostate	2018	SICBL	NHS Surrey Heartlands ICB - 92A	4.7	0.3	0.8	94.3
Prostate	2019	SICBL	NHS Surrey Heartlands ICB - 92A	5.3	0.2	0.8	93.7
Prostate	2020	SICBL	NHS Surrey Heartlands ICB - 92A	5.5	0.6	1.4	92.6

Routes to diagnosis – NHS Frimley ICB (2013-2020): visual representation over time (data on following slide)


All malignant neoplasms




Breast




Colorectal




Lung non-small cell



Lung – small-cell



Prostate



Routes to diagnosis – sub ICB level - FH

Only cancer sites data available for for SH and FH:
All malignant neoplasms; breast; colorectal; lung – NSC; lung – SC; prostate 2013 - 2020

Topline insights - In FH vs SH v England

- Similar to England, of the 5 selected cancers, **lung cancers (small cell and non-small cell) have the highest proportion of emergency presentation with only around ~60 - 70% diagnosed via non-emergency routes**, and up to 40% being diagnosed via A&E emergency presentation (comparatively slightly higher than SH and England)
- Compared to England, a similar, but slightly relatively higher proportion of colorectal cancers are diagnosed via non-emergency routes (similar to SH) (~20 - 25%)
- Similar to England, >90% breast and prostate cancers diagnosed by non-emergency routes
- Outperforming England, 80-84% all malignant neoplasms diagnosed via non-emergency routes

Site	Year	Area	Geography	A and E (%)	GP EP (%)	Other EP (%)	All other routes (%)
All Malignant Neoplasms (excl. NMSC)	2013	SICBL	NHS Frimley ICB - D4U1Y	13.9	2.0	3.0	81.1
All Malignant Neoplasms (excl. NMSC)	2014	SICBL	NHS Frimley ICB - D4U1Y	14.1	1.9	2.7	81.3
All Malignant Neoplasms (excl. NMSC)	2015	SICBL	NHS Frimley ICB - D4U1Y	13.0	2.0	2.8	82.3
All Malignant Neoplasms (excl. NMSC)	2016	SICBL	NHS Frimley ICB - D4U1Y	14.0	2.0	2.9	81.1
All Malignant Neoplasms (excl. NMSC)	2017	SICBL	NHS Frimley ICB - D4U1Y	12.8	1.1	2.6	83.4
All Malignant Neoplasms (excl. NMSC)	2018	SICBL	NHS Frimley ICB - D4U1Y	12.7	1.5	3.0	82.8
All Malignant Neoplasms (excl. NMSC)	2019	SICBL	NHS Frimley ICB - D4U1Y	11.9	1.7	3.4	83.1
All Malignant Neoplasms (excl. NMSC)	2020	SICBL	NHS Frimley ICB - D4U1Y	15.6	1.1	3.2	80.1

Breast	2013	SICBL	NHS Frimley ICB - D4U1Y	2.5	0.2	0.5	96.8
Breast	2014	SICBL	NHS Frimley ICB - D4U1Y	1.3	0.1	0.7	97.8
Breast	2015	SICBL	NHS Frimley ICB - D4U1Y	1.8	0.3	0.2	97.7
Breast	2016	SICBL	NHS Frimley ICB - D4U1Y	2.1	0.8	0.3	96.7
Breast	2017	SICBL	NHS Frimley ICB - D4U1Y	2.5	0.3	0.0	97.2
Breast	2018	SICBL	NHS Frimley ICB - D4U1Y	1.0	0.2	0.3	98.5
Breast	2019	SICBL	NHS Frimley ICB - D4U1Y	3.2	0.5	0.5	95.8
Breast	2020	SICBL	NHS Frimley ICB - D4U1Y	4.6	0.3	0.3	94.7

Colorectal	2013	SICBL	NHS Frimley ICB - D4U1Y	16.3	3.2	3.0	77.5
Colorectal	2014	SICBL	NHS Frimley ICB - D4U1Y	20.3	2.1	1.5	76.2
Colorectal	2015	SICBL	NHS Frimley ICB - D4U1Y	14.3	3.9	1.8	80.0
Colorectal	2016	SICBL	NHS Frimley ICB - D4U1Y	20.1	3.5	3.7	72.7
Colorectal	2017	SICBL	NHS Frimley ICB - D4U1Y	18.5	1.5	2.6	77.4
Colorectal	2018	SICBL	NHS Frimley ICB - D4U1Y	17.0	2.2	3.9	76.9
Colorectal	2019	SICBL	NHS Frimley ICB - D4U1Y	14.9	1.2	3.9	80.0
Colorectal	2020	SICBL	NHS Frimley ICB - D4U1Y	18.2	1.3	3.5	77.0


Lung - non-small cell	2013	SICBL	NHS Frimley ICB - D4U1Y	25.2	2.6	2.6	69.5
Lung - non-small cell	2014	SICBL	NHS Frimley ICB - D4U1Y	26.0	3.1	3.1	67.7
Lung - non-small cell	2015	SICBL	NHS Frimley ICB - D4U1Y	24.2	3.6	4.6	67.5
Lung - non-small cell	2016	SICBL	NHS Frimley ICB - D4U1Y	27.6	2.6	3.4	66.4
Lung - non-small cell	2017	SICBL	NHS Frimley ICB - D4U1Y	24.8	0.3	5.2	69.7
Lung - non-small cell	2018	SICBL	NHS Frimley ICB - D4U1Y	24.4	1.4	4.9	69.3
Lung - non-small cell	2019	SICBL	NHS Frimley ICB - D4U1Y	21.7	3.8	4.1	70.5
Lung - non-small cell	2020	SICBL	NHS Frimley ICB - D4U1Y	31.7	1.1	3.4	63.7

Lung - small cell	2013	SICBL	NHS Frimley ICB - D4U1Y	40.7	0.0	0.0	59.3
Lung - small cell	2014	SICBL	NHS Frimley ICB - D4U1Y	35.5	0.0	3.2	61.3
Lung - small cell	2015	SICBL	NHS Frimley ICB - D4U1Y	32.1	3.6	0.0	64.3
Lung - small cell	2016	SICBL	NHS Frimley ICB - D4U1Y	19.2	3.8	0.0	76.9
Lung - small cell	2017	SICBL	NHS Frimley ICB - D4U1Y	39.4	3.0	0.0	57.6
Lung - small cell	2018	SICBL	NHS Frimley ICB - D4U1Y	18.4	5.3	0.0	76.3
Lung - small cell	2019	SICBL	NHS Frimley ICB - D4U1Y	23.1	11.5	7.7	57.7
Lung - small cell	2020	SICBL	NHS Frimley ICB - D4U1Y	31.4	0.0	0.0	68.6

Prostate	2013	SICBL	NHS Frimley ICB - D4U1Y	3.3	0.9	2.4	93.5
Prostate	2014	SICBL	NHS Frimley ICB - D4U1Y	5.8	0.9	1.9	91.4
Prostate	2015	SICBL	NHS Frimley ICB - D4U1Y	5.3	0.2	2.3	92.2
Prostate	2016	SICBL	NHS Frimley ICB - D4U1Y	6.7	0.2	1.7	91.4
Prostate	2017	SICBL	NHS Frimley ICB - D4U1Y	5.5	0.4	0.8	93.4
Prostate	2018	SICBL	NHS Frimley ICB - D4U1Y	4.7	0.2	1.7	93.4
Prostate	2019	SICBL	NHS Frimley ICB - D4U1Y	3.4	0.6	1.3	94.7
Prostate	2020	SICBL	NHS Frimley ICB - D4U1Y	6.6	0.2	0.2	93.0

Routes to diagnosis – National (2020) – variations by deprivation: barchart (data on following slide)

Proportion of cancers diagnosed by emergency presentation (%) by cancer type and deprivation quintile (IMD2019)




Routes to diagnosis – National (2020) – variations by deprivation:

Proportion of cancers diagnosed by emergency presentation (%) by cancer type and deprivation quintile (IMD2019)

Year	Site	Deprivation Quintile	Count	Percentage	LCI	UCI	Difference IMD1-IMD5
2020	All Malignant Neoplasms (excl. NMSC)	1 - most deprived	13844	27.3	26.9	27.7	7.9
2020	All Malignant Neoplasms (excl. NMSC)	5 - least deprived	11975	19.4	19.0	19.7	
2020	Biliary tract	1 - most deprived	475	55.9	52.6	59.3	8.4
2020	Biliary tract	5 - least deprived	396	47.5	44.2	50.9	
2020	Bladder	1 - most deprived	495	18.9	17.4	20.4	6.2
2020	Bladder	5 - least deprived	464	12.7	11.6	13.8	
2020	Bone	1 - most deprived	26	28.6	20.3	38.6	12.4
2020	Bone	5 - least deprived	18	16.2	10.5	24.2	
2020	Brain	1 - most deprived	770	47.2	44.8	49.7	4.9
2020	Brain	5 - least deprived	830	42.3	40.2	44.5	
2020	Breast	1 - most deprived	381	6.3	5.7	7.0	2.2
2020	Breast	5 - least deprived	388	4.1	3.7	4.5	
2020	Cancer of unknown primary	1 - most deprived	760	61.0	58.3	63.7	3.9
2020	Cancer of unknown primary	5 - least deprived	669	57.1	54.3	59.9	
2020	Cervix	1 - most deprived	94	14.8	12.3	17.8	5.5
2020	Cervix	5 - least deprived	32	9.3	6.7	12.9	
2020	Colorectal	1 - most deprived	1591	29.1	28.0	30.4	7.3
2020	Colorectal	5 - least deprived	1687	21.8	20.9	22.7	
2020	Haematology - ALL	1 - most deprived	104	66.7	58.9	73.6	-1.7
2020	Haematology - ALL	5 - least deprived	106	68.4	60.7	75.2	
2020	Haematology - AML	1 - most deprived	222	65.1	59.9	70.0	7.3
2020	Haematology - AML	5 - least deprived	303	57.8	53.6	62.0	
2020	Haematology - CLL or SLL	1 - most deprived	91	18.8	15.5	22.5	2.3
2020	Haematology - CLL or SLL	5 - least deprived	124	16.4	14.0	19.2	
2020	Haematology - CML	1 - most deprived	36	34.0	25.6	43.4	-0.2
2020	Haematology - CML	5 - least deprived	41	34.2	26.3	43.0	
2020	Haematology - CMML	1 - most deprived	21	37.5	26.0	50.6	11.0
2020	Haematology - CMML	5 - least deprived	26	26.5	18.8	36.0	
2020	Haematology - ET	1 - most deprived	37	18.9	14.0	24.9	5.7
2020	Haematology - ET	5 - least deprived	36	13.2	9.7	17.7	
2020	Haematology - Follicular lymphoma	1 - most deprived	52	16.9	13.1	21.5	5.5
2020	Haematology - Follicular lymphoma	5 - least deprived	57	11.4	8.9	14.4	
2020	Haematology - Hodgkin lymphoma	1 - most deprived	89	25.0	20.8	29.7	1.5
2020	Haematology - Hodgkin lymphoma	5 - least deprived	84	23.5	19.4	28.2	
2020	Haematology - LPL or Waldenstrom	1 - most deprived	12	20.3	12.0	32.3	6.7
2020	Haematology - LPL or Waldenstrom	5 - least deprived	25	13.7	9.4	19.4	
2020	Haematology - MCL	1 - most deprived	20	27.8	18.8	39.0	8.9
2020	Haematology - MCL	5 - least deprived	23	18.9	12.9	26.7	
2020	Haematology - MDS	1 - most deprived	124	35.7	30.9	40.9	7.5
2020	Haematology - MDS	5 - least deprived	152	28.3	24.6	32.2	
2020	Haematology - Marginal zone lymphoma	1 - most deprived	39	22.9	17.3	29.8	12.0
2020	Haematology - Marginal zone lymphoma	5 - least deprived	25	11.0	7.5	15.7	
2020	Haematology - Mature T-cell and NK-cell neoplasms	1 - most deprived	61	35.5	28.7	42.9	10.2
2020	Haematology - Mature T-cell and NK-cell neoplasms	5 - least deprived	56	25.2	20.0	31.3	

Year	Site	Deprivation Quintile	Count	Percentage	LCI	UCI	Difference IMD1-IMD5
2020	Haematology - Myeloma	1 - most deprived	266	38.2	34.6	41.8	2.9
2020	Haematology - Myeloma	5 - least deprived	395	35.3	32.6	38.1	
2020	Haematology - Other	1 - most deprived	224	33.2	29.8	36.9	1.4
2020	Haematology - Other	5 - least deprived	285	31.8	28.8	34.9	
2020	Haematology - PCV	1 - most deprived	23	22.8	15.7	31.9	4.8
2020	Haematology - PCV	5 - least deprived	29	18.0	12.8	24.7	
2020	Head and neck	1 - most deprived	281	12.5	11.2	13.9	5.4
2020	Head and neck	5 - least deprived	124	7.1	6.0	8.4	
2020	Kaposi sarcoma	1 - most deprived	4	20.0	8.1	41.6	10.0
2020	Kaposi sarcoma	5 - least deprived	1	10.0	1.8	40.4	
2020	Kidney	1 - most deprived	487	29.6	27.4	31.8	6.7
2020	Kidney	5 - least deprived	420	22.9	21.0	24.9	
2020	Liver	1 - most deprived	333	41.5	38.1	44.9	3.2
2020	Liver	5 - least deprived	226	38.2	34.4	42.2	
2020	Lung - non-small cell	1 - most deprived	3380	38.4	37.4	39.5	4.1
2020	Lung - non-small cell	5 - least deprived	1790	34.3	33.1	35.6	
2020	Lung - small cell	1 - most deprived	330	35.8	32.8	39.0	1.9
2020	Lung - small cell	5 - least deprived	156	33.9	29.7	38.4	
2020	Melanoma	1 - most deprived	46	3.5	2.7	4.7	1.1
2020	Melanoma	5 - least deprived	85	2.4	2.0	3.0	
2020	Oesophagus	1 - most deprived	422	26.2	24.1	28.4	6.0
2020	Oesophagus	5 - least deprived	324	20.1	18.2	22.2	
2020	Ovary	1 - most deprived	389	33.7	31.0	36.5	4.3
2020	Ovary	5 - least deprived	419	29.4	27.1	31.8	
2020	Pancreas	1 - most deprived	777	50.6	48.1	53.1	10.2
2020	Pancreas	5 - least deprived	814	40.4	38.3	42.5	
2020	Prostate	1 - most deprived	553	11.8	10.9	12.8	4.4
2020	Prostate	5 - least deprived	662	7.5	6.9	8.0	
2020	Renal pelvis and ureter	1 - most deprived	80	20.3	16.6	24.6	5.1
2020	Renal pelvis and ureter	5 - least deprived	76	15.2	12.3	18.6	
2020	Soft tissue	1 - most deprived	75	25.1	20.5	30.3	12.2
2020	Soft tissue	5 - least deprived	50	12.9	9.9	16.6	
2020	Stomach	1 - most deprived	340	39.1	35.9	42.4	3.7
2020	Stomach	5 - least deprived	254	35.5	32.1	39.0	
2020	Testis	1 - most deprived	60	15.6	12.3	19.6	7.1
2020	Testis	5 - least deprived	31	8.5	6.1	11.9	
2020	Urethra	1 - most deprived	12	19.0	11.2	30.4	11.7
2020	Urethra	5 - least deprived	8	7.3	3.8	13.8	
2020	Uterus	1 - most deprived	179	13.2	11.5	15.1	5.8
2020	Uterus	5 - least deprived	119	7.4	6.2	8.8	

Routes to diagnosis – National (2020) – variations by ethnicity: barchart (data on following slide)




Routes to diagnosis – National (2020) – variations by ethnicity:

Proportion of cancers diagnosed by emergency presentation (%) by cancer type and ethnic group

Year	Site	Ethnicity	Percentage	LCI	UCI	Difference vs White ethnic group
2020	All Malignant Neoplasms (excl. NMSC)	Asian excluding Chinese	21.8	20.91451739	22.73125336	0.879546567
2020	All Malignant Neoplasms (excl. NMSC)	Black	21.7	20.60943118	22.75104364	1.027699901
2020	All Malignant Neoplasms (excl. NMSC)	Chinese	23.1	20.21060325	26.21618624	-0.388128684
2020	All Malignant Neoplasms (excl. NMSC)	Mixed	19.8	17.83375626	21.86673678	2.915915302
2020	All Malignant Neoplasms (excl. NMSC)	Other ethnicity	22.3	21.09950658	23.61098179	0.358697306
2020	All Malignant Neoplasms (excl. NMSC)	Unknown ethnicity	20.6	19.98935089	21.29866789	2.052467918
2020	All Malignant Neoplasms (excl. NMSC)	White	22.7	22.52632536	22.85208958	
2020	Breast	Asian excluding Chinese	3.7	2.838616266	4.738458398	1.154554857
2020	Breast	Black	5.6	4.303168208	7.282205198	-0.782806984
2020	Breast	Chinese	5.2	2.655493249	9.915005636	-0.36811919
2020	Breast	Mixed	2.4	1.190546173	4.96504623	2.379133557
2020	Breast	Other ethnicity	3.7	2.529810793	5.277724562	1.163185326
2020	Breast	Unknown ethnicity	5.5	4.612787512	6.576647832	-0.686257428
2020	Breast	White	4.8	4.605431091	5.058006883	
2020	Colorectal	Asian excluding Chinese	21.3	18.47298899	24.3912466	3.351116163
2020	Colorectal	Black	23.9	20.52387525	27.58980368	0.75559984
2020	Colorectal	Chinese	25.5	18.02965842	34.72987404	-0.856678824
2020	Colorectal	Mixed	23.6	17.52379582	31.10683471	0.984868606
2020	Colorectal	Other ethnicity	24.9	20.95859295	29.26176082	-0.245709798
2020	Colorectal	Unknown ethnicity	22.5	20.64843593	24.48682034	2.123885995
2020	Colorectal	White	24.6	24.15417729	25.1192193	
2020	Lung - non-small cell	Asian excluding Chinese	34.6	30.77573638	38.53992267	2.037394166
2020	Lung - non-small cell	Black	33.3	29.00874469	37.95791305	3.259034655
2020	Lung - non-small cell	Chinese	35.7	26.29936447	46.37868491	0.878082274
2020	Lung - non-small cell	Mixed	36.4	28.31207447	45.42428727	0.151690022
2020	Lung - non-small cell	Other ethnicity	36.9	32.10221856	41.94071316	-0.292877914
2020	Lung - non-small cell	Unknown ethnicity	41.4	38.8616867	44.02828277	-4.82902469
2020	Lung - non-small cell	White	36.6	36.05786049	37.13019786	
2020	Lung - small cell	Asian excluding Chinese	45.9	31.0385698	61.61595311	-10.24574871
2020	Lung - small cell	Black	32.0	17.20519031	51.58973073	3.700197239
2020	Lung - small cell	Chinese	66.7	20.76596008	93.85080553	-30.96646943
2020	Lung - small cell	Mixed	50.0	26.79920245	73.20079755	-14.29980276
2020	Lung - small cell	Other ethnicity	38.2	23.90018332	54.95898266	-2.535096879
2020	Lung - small cell	Unknown ethnicity	45.9	36.81716204	55.207046	-10.17136239
2020	Lung - small cell	White	35.7	34.01662652	37.41983819	
2020	Prostate	Asian excluding Chinese	7.5	5.83398269	9.679103612	1.8
2020	Prostate	Black	8.5	7.111535818	10.22733551	0.8
2020	Prostate	Chinese	13.3	6.914109481	24.16515968	-4.0
2020	Prostate	Mixed	9.1	5.586635383	14.45669939	0.2
2020	Prostate	Other ethnicity	9.4	7.058469122	12.51224056	-0.1
2020	Prostate	Unknown ethnicity	7.4	6.406893057	8.531840626	1.9
2020	Prostate	White	9.3	8.973874523	9.619872457	

Routes to diagnosis – National (2020) – variations by age: barchart (data on following slide)

Proportion of cancers diagnosed by emergency presentation (%) by cancer type and age



Routes to diagnosis – National (2020) – variations by age:


Proportion of cancers diagnosed by emergency presentation (%) by cancer type and age group

Year	Site	Age group	Count	Percentage	LCI	UCI
2020	All Malignant Neoplasms (excl. NMSC)	0 to 49	4942	16.7	16.32462	17.17663
2020	All Malignant Neoplasms (excl. NMSC)	50 to 59	5975	15.1	14.70649	15.41013
2020	All Malignant Neoplasms (excl. NMSC)	60 to 69	11124	17.0	16.6726	17.24694
2020	All Malignant Neoplasms (excl. NMSC)	70 to 79	19193	21.9	21.60699	22.15416
2020	All Malignant Neoplasms (excl. NMSC)	80 to 84	10083	30.4	29.85917	30.84794
2020	All Malignant Neoplasms (excl. NMSC)	85 plus	13712	41.5	41.00584	42.06895
2020	Biliary tract	0 to 49	65	41.9	34.45421	49.80683
2020	Biliary tract	50 to 59	171	45.7	40.74218	50.78866
2020	Biliary tract	60 to 69	360	45.0	41.58467	48.46312
2020	Biliary tract	70 to 79	683	49.0	46.41195	51.65511
2020	Biliary tract	80 to 84	388	57.7	53.96967	61.41856
2020	Biliary tract	85 plus	509	65.8	62.34892	69.01994
2020	Bladder	0 to 49	65	12.2	9.721314	15.3032
2020	Bladder	50 to 59	128	9.4	8.001843	11.12044
2020	Bladder	60 to 69	324	10.1	9.090045	11.17336
2020	Bladder	70 to 79	723	12.1	11.3435	13.00377
2020	Bladder	80 to 84	496	17.7	16.31529	19.13853
2020	Bladder	85 plus	745	27.8	26.11535	29.50378
2020	Bone	0 to 49	50	18.9	14.61476	24.01078
2020	Bone	50 to 59	7	10.8	5.315422	20.60131
2020	Bone	60 to 69	11	16.7	9.569583	27.43059
2020	Bone	70 to 79	13	21.0	12.68399	32.63921
2020	Bone	80 to 84	3	17.6	6.191127	41.02946
2020	Bone	85 plus	5	25.0	11.18617	46.87009
2020	Brain	0 to 49	899	36.7	34.85091	38.66839
2020	Brain	50 to 59	501	33.2	30.8908	35.64008
2020	Brain	60 to 69	696	39.0	36.7759	41.29822
2020	Brain	70 to 79	1021	49.1	46.9879	51.28286
2020	Brain	80 to 84	464	65.6	62.0525	69.03742
2020	Brain	85 plus	546	76.0	72.78928	79.02265
2020	Breast	0 to 49	164	2.1	1.813476	2.45412
2020	Breast	50 to 59	152	1.7	1.458119	1.99729
2020	Breast	60 to 69	258	3.0	2.629298	3.343254
2020	Breast	70 to 79	477	5.9	5.403506	6.430695
2020	Breast	80 to 84	322	10.0	9.042039	11.12209
2020	Breast	85 plus	556	15.8	14.64898	17.06115
2020	Cancer of unknown primary	0 to 49	85	39.4	33.07743	45.9984
2020	Cancer of unknown primary	50 to 59	211	45.6	41.09087	50.1267
2020	Cancer of unknown primary	60 to 69	488	53.1	49.86655	56.30803
2020	Cancer of unknown primary	70 to 79	1067	58.3	56.00052	60.51317
2020	Cancer of unknown primary	80 to 84	647	61.7	58.75625	64.63131
2020	Cancer of unknown primary	85 plus	1152	68.0	65.74484	70.18313
2020	Cervix	0 to 49	104	7.6	6.281212	9.082517
2020	Cervix	50 to 59	48	12.3	9.43454	15.98066
2020	Cervix	60 to 69	43	16.0	12.13534	20.91387
2020	Cervix	70 to 79	47	24.1	18.63703	30.56873
2020	Cervix	80 to 84	19	25.0	16.62893	35.77675
2020	Cervix	85 plus	15	21.7	13.64077	32.8183
2020	Colorectal	0 to 49	564	27.2	25.33469	29.16352
2020	Colorectal	50 to 59	841	22.1	20.85678	23.49765
2020	Colorectal	60 to 69	1274	16.4	15.5898	17.2362
2020	Colorectal	70 to 79	2254	20.8	20.00457	21.53006
2020	Colorectal	80 to 84	1377	28.0	26.80584	29.3181
2020	Colorectal	85 plus	2097	42.0	40.65293	43.90611
2020	Haematology - ALL	0 to 49	392	69.9	65.95401	73.52609
2020	Haematology - ALL	50 to 59	25	50.0	36.64451	63.35549
2020	Haematology - ALL	60 to 69	33	62.3	48.8069	74.06373
2020	Haematology - ALL	70 to 79	27	55.1	41.31511	68.14716
2020	Haematology - ALL	80 to 84	15	48.4	31.97025	65.1596
2020	Haematology - ALL	85 plus	5	50.0	23.65931	76.34069
2020	Haematology - AML	0 to 49	230	67.1	61.91646	71.81653
2020	Haematology - AML	50 to 59	137	65.9	59.18609	71.96928
2020	Haematology - AML	60 to 69	248	58.9	54.14768	63.50596
2020	Haematology - AML	70 to 79	352	54.2	50.39064	58.03407
2020	Haematology - AML	80 to 84	135	53.1	47.01164	59.19372
2020	Haematology - AML	85 plus	178	60.8	55.05507	66.16838
2020	Haematology - CLL or SLL	0 to 49	16	11.4	7.158261	17.75907
2020	Haematology - CLL or SLL	50 to 59	45	12.2	9.265809	15.97115
2020	Haematology - CLL or SLL	60 to 69	107	13.5	11.33375	16.10768
2020	Haematology - CLL or SLL	70 to 79	174	15.9	13.83202	18.15818
2020	Haematology - CLL or SLL	80 to 84	94	22.6	18.83964	26.85515
2020	Haematology - CLL or SLL	85 plus	156	36.9	32.41887	41.57616

Year	Site	Age group	Count	Percentage	LCI	UCI
2020	Haematology - CML	0 to 49	76	44.4	37.20006	51.93295
2020	Haematology - CML	50 to 59	30	29.1	21.22894	38.52451
2020	Haematology - CML	60 to 69	26	22.6	15.92164	31.06656
2020	Haematology - CML	70 to 79	40	31.5	24.06176	40.0169
2020	Haematology - CML	80 to 84	17	34.0	22.43695	47.84617
2020	Haematology - CML	85 plus	26	55.3	41.24548	68.58903
2020	Haematology - CMML	0 to 49	0	0.0	0	48.98908
2020	Haematology - CMML	50 to 59	5	31.3	14.16464	55.59564
2020	Haematology - CMML	60 to 69	16	22.5	14.37467	33.51518
2020	Haematology - CMML	70 to 79	39	25.5	19.24372	32.93729
2020	Haematology - CMML	80 to 84	31	37.3	27.71969	48.09831
2020	Haematology - CMML	85 plus	45	52.3	41.89783	62.55446
2020	Haematology - ET	0 to 49	16	10.3	6.412257	16.01087
2020	Haematology - ET	50 to 59	24	16.1	11.06954	22.84892
2020	Haematology - ET	60 to 69	30	12.3	8.749673	17.00392
2020	Haematology - ET	70 to 79	57	15.7	12.35591	19.85516
2020	Haematology - ET	80 to 84	22	15.2	10.23817	21.90444
2020	Haematology - ET	85 plus	39	28.7	21.74373	36.78073
2020	Haematology - Follicular lymphoma	0 to 49	27	11.6	8.12269	16.4029
2020	Haematology - Follicular lymphoma	50 to 59	49	13.0	9.945951	16.72519
2020	Haematology - Follicular lymphoma	60 to 69	80	14.5	11.77973	17.64363
2020	Haematology - Follicular lymphoma	70 to 79	87	13.4	10.98106	16.21842
2020	Haematology - Follicular lymphoma	80 to 84	36	17.6	12.96292	23.35241
2020	Haematology - Follicular lymphoma	85 plus	23	21.1	14.49236	29.6771
2020	Haematology - Hodgkin lymphoma	0 to 49	201	20.1	17.76874	22.7408
2020	Haematology - Hodgkin lymphoma	50 to 59	43	20.1	15.27373	25.96794
2020	Haematology - Hodgkin lymphoma	60 to 69	41	20.8	15.72829	27.01262
2020	Haematology - Hodgkin lymphoma	70 to 79	58	31.4	25.10311	38.3583
2020	Haematology - Hodgkin lymphoma	80 to 84	27	35.1	25.34868	46.20058
2020	Haematology - Hodgkin lymphoma	85 plus	23	46.9	33.7035	60.61914
2020	Haematology - LPL or Waldenstrom	0 to 49	3	27.3	9.746059	56.56453
2020	Haematology - LPL or Waldenstrom	50 to 59	10	18.9	10.58533	31.35846
2020	Haematology - LPL or Waldenstrom	60 to 69	23	14.7	10.0297	21.15211
2020	Haematology - LPL or Waldenstrom	70 to 79	28	12.3	8.673534	17.24965
2020	Haematology - LPL or Waldenstrom	80 to 84	18	16.5	10.70869	24.59878
2020	Haematology - LPL or Waldenstrom	85 plus	9	11.3	6.032687	20.01822
2020	Haematology - MCL	0 to 49	6	27.3	13.15076	48.15173
2020	Haematology - MCL	50 to 59	14	22.6	13.95518	34.40562
2020	Haematology - MCL	60 to 69	22	17.9	12.11886	25.59867
2020	Haematology - MCL	70 to 79	43	24.3	18.56557	31.14411
2020	Haematology - MCL	80 to 84	15	22.1	13.84901	33.25674
2020	Haematology - MCL	85 plus	16	27.6	17.75235	40.20466
2020	Haematology - MDS	0 to 49	26	30.2	21.54352	40.61203
2020	Haematology - MDS	50 to 59	32	27.8	20.45389	36.63179
2020	Haematology - MDS	60 to 69	84	25.1	20.79712	30.06741
2020	Haematology - MDS	70 to 79	195	27.6	24.45008	31.03294
2020	Haematology - MDS	80 to 84	155	35.2	30.90934	39.80093
2020	Haematology - MDS	85 plus	293	48.3	44.31832	52.2438
2020	Haematology - Marginal zone lymphoma	0 to 49	17	19.3	12.42596	28.77707
2020	Haematology - Marginal zone lymphoma	50 to 59	22	15.4	10.38465	22.1957
2020	Haematology - Marginal zone lymphoma	60 to 69	35	15.7	11.50685	21.04516
2020	Haematology - Marginal zone lymphoma	70 to 79	53	15.4	11.97595	19.60208
2020	Haematology - Marginal zone lymphoma	80 to 84	34	22.1	16.25125	29.2637
2020	Haematology - Marginal zone lymphoma	85 plus	20	23.5	15.77954	33.56843
2020	Haematology - Mature T-cell and NK-cell neoplasms	0 to 49	61	34.3	27.69571	41.50823
2020	Haematology - Mature T-cell and NK-cell neoplasms	50 to 59	33	24.3	17.83153	32.11179
2020	Haematology - Mature T-cell and NK-cell neoplasms	60 to 69	57	22.9	18.10847	28.49838
2020	Haematology - Mature T-cell and NK-cell neoplasms	70 to 79	83	30.4	25.24946	36.10026
2020	Haematology - Mature T-cell and NK-cell neoplasms	80 to 84	37	35.9	27.31709	45.53989
2020	Haematology - Mature T-cell and NK-cell neoplasms	85 plus	34	41.5	31.41656	52.2743
2020	Haematology - Myeloma	0 to 49	65	33.3	27.09519	40.21545
2020	Haematology - Myeloma	50 to 59	199	34.0	30.24031	37.88671
2020	Haematology - Myeloma	60 to 69	350	32.7	29.96541	35.57886
2020	Haematology - Myeloma	70 to 79	498	32.0	29.69524	34.3216
2020	Haematology - Myeloma	80 to 84	242	36.2	32.6208	39.88387
2020	Haematology - Myeloma	85 plus	300	45.2	41.43388	48.983
2020	Haematology - Other	0 to 49	229	37.2	33.50533	41.12469
2020	Haematology - Other	50 to 59	125	27.7	23.73274	31.95361
2020	Haematology - Other	60 to 69	173	22.8	19.95013	25.91018
2020	Haematology - Other	70 to 79	362	30.7	28.11298	33.36835
2020	Haematology - Other	80 to 84	198	35.9	32.03848	40.02561
2020	Haematology - Other	85 plus	301	47.0	43.19359	50.90434

Year	Site	Age group	Count	Percentage	LCI	UCI
2020	Haematology - PCV	0 to 49	10	16.4	9.156012	27.61284
2020	Haematology - PCV	50 to 59	13	12.4	7.380164	20.0372
2020	Haematology - PCV	60 to 69	16	11.9	7.428349	18.38632
2020	Haematology - PCV	70 to 79	38	18.1	13.47677	23.85998
2020	Haematology - PCV	80 to 84	19	22.1	14.62491	31.94764
2020	Haematology - PCV	85 plus	24	33.3	23.53464	44.8204
2020	Head and neck	0 to 49	95	9.9	8.198219	11.99693
2020	Head and neck	50 to 59	185	7.6	6.60247	8.707347
2020	Head and neck	60 to 69	244	8.3	7.370817	9.370776
2020	Head and neck	70 to 79	263	11.0	9.803331	12.31172
2020	Head and neck	80 to 84	89	15.0	12.	

Routes to diagnosis – National (2020) – variations by gender: barchart (data on following slide)



Routes to diagnosis – National (2020) – variations by gender:

Proportion of cancers diagnosed by emergency presentation (%) by cancer type and gender

Year	Site	Gender	Count	Percentage	LCI	UCI
2020	All Malignant Neoplasms (excl. NMSC)	Male	34895	23.54445412	23.32914	23.76114
2020	All Malignant Neoplasms (excl. NMSC)	Female	30134	21.44112478	21.22734	21.65647
2020	Biliary tract	Male	1020	51.80294566	49.59453	54.00434
2020	Biliary tract	Female	1156	52.5693497	50.47964	54.6501
2020	Bladder	Male	1721	13.84330759	13.24739	14.46156
2020	Bladder	Female	760	18.51400731	17.35545	19.73144
2020	Bone	Male	55	19.23076923	15.08307	24.19408
2020	Bone	Female	34	16.26794258	11.88122	21.87228
2020	Brain	Male	2045	45.58626839	44.13323	47.04686
2020	Brain	Female	2082	43.77628259	42.37191	45.1907
2020	Breast	Male	21	6.542056075	4.318385	9.793563
2020	Breast	Female	1908	4.785673079	4.580461	4.999598
2020	Cancer of unknown primary	Male	1727	57.43265713	55.65702	59.18933
2020	Cancer of unknown primary	Female	1923	60.77749684	59.06416	62.4647
2020	Cervix	Female	276	11.63575042	10.40693	12.98863
2020	Colorectal	Male	4247	22.34087322	21.75438	22.93854
2020	Colorectal	Female	4160	27.03053931	26.33468	27.73787
2020	Haematology - ALL	Male	316	68.69565217	64.31781	72.76383
2020	Haematology - ALL	Female	181	61.56462585	55.88904	66.9419
2020	Haematology - AML	Male	710	59.61376994	56.80052	62.3652
2020	Haematology - AML	Female	570	58.34186285	55.22378	61.3946
2020	Haematology - CLL or SLL	Male	392	18.85521886	17.23185	20.59347
2020	Haematology - CLL or SLL	Female	200	17.33102253	15.25647	19.62236
2020	Haematology - CML	Male	132	36.76880223	31.94561	41.87216
2020	Haematology - CML	Female	83	32.67716535	27.20444	38.66606
2020	Haematology - CMML	Male	91	32.38434164	27.1825	38.06133
2020	Haematology - CMML	Female	45	34.09090909	26.55691	42.52469
2020	Haematology - ET	Male	78	15.69416499	12.76081	19.15377
2020	Haematology - ET	Female	110	15.82733813	13.30254	18.72782
2020	Haematology - Follicular lymphoma	Male	168	15.45538178	13.42847	17.72559
2020	Haematology - Follicular lymphoma	Female	134	12.88461538	10.9842	15.05821
2020	Haematology - Hodgkin lymphoma	Male	250	25.6147541	22.97556	28.44515
2020	Haematology - Hodgkin lymphoma	Female	143	19.22043011	16.55004	22.20703
2020	Haematology - LPL or Waldenstrom	Male	62	14.58823529	11.54955	18.26134
2020	Haematology - LPL or Waldenstrom	Female	29	13.74407583	9.742869	19.04183
2020	Haematology - Marginal zone lymphoma	Male	93	18.63727455	15.46486	22.28888
2020	Haematology - Marginal zone lymphoma	Female	88	16.35687732	13.47185	19.71894
2020	Haematology - Mature T-cell and NK-cell neoplasms	Male	191	29.07153729	25.72892	32.65746
2020	Haematology - Mature T-cell and NK-cell neoplasms	Female	114	31.31868132	26.77019	36.25736
2020	Haematology - MCL	Male	78	21.48760331	17.57246	25.99989
2020	Haematology - MCL	Female	38	25.85034014	19.45159	33.47913
2020	Haematology - MDS	Male	509	34.50847458	32.12544	36.97199
2020	Haematology - MDS	Female	276	33.94833948	30.77559	37.27206
2020	Haematology - Myeloma	Male	950	34.65888362	32.89994	36.46077
2020	Haematology - Myeloma	Female	704	35.1824088	33.12027	37.30134
2020	Haematology - Other	Male	807	33.92181589	32.04662	35.84886
2020	Haematology - Other	Female	581	31.95819582	29.85463	34.13785
2020	Haematology - PCV	Male	65	16.66666667	13.29684	20.68675
2020	Haematology - PCV	Female	55	19.71326165	15.47003	24.77918

Year	Site	Gender	Count	Percentage	LCI	UCI
2020	Head and neck	Male	682	10.02204262	9.330965	10.75823
2020	Head and neck	Female	280	9.126466754	8.157898	10.19726
2020	Kaposi sarcoma	Male	9	11.25	6.032687	20.01822
2020	Kaposi sarcoma	Female	3	37.5	13.68443	69.42576
2020	Kidney	Male	1440	25.09147935	23.98674	26.22954
2020	Kidney	Female	863	26.55384615	25.06388	28.09917
2020	Liver	Male	990	38.61154446	36.74544	40.51173
2020	Liver	Female	414	44.90238612	41.71955	48.12752
2020	Lung - non-small cell	Male	6574	37.45868946	36.74541	38.17745
2020	Lung - non-small cell	Female	5894	35.92150171	35.19078	36.65882
2020	Lung - small cell	Male	586	36.60212367	34.27718	38.99121
2020	Lung - small cell	Female	597	35.89897775	33.62835	38.2346
2020	Melanoma	Male	211	3.336495889	2.921435	3.808213
2020	Melanoma	Female	149	2.397039897	2.045179	2.807701
2020	Oesophagus	Male	1308	22.47036592	21.41649	23.56055
2020	Oesophagus	Female	582	24.26010838	22.58683	26.01569
2020	Ovary	Female	1976	30.41403725	29.30724	31.54398
2020	Pancreas	Male	2147	44.2042413	42.81269	45.60496
2020	Pancreas	Female	2068	45.83333333	44.38364	47.29012
2020	Prostate	Male	3283	9.115140073	8.822234	9.416766
2020	Renal pelvis and ureter	Male	245	16.83848797	15.00358	18.84804
2020	Renal pelvis and ureter	Female	170	19.58525346	17.08158	22.35695
2020	Soft tissue	Male	174	16.90962099	14.7434	19.32199
2020	Soft tissue	Female	149	19.07810499	16.4764	21.98251
2020	Stomach	Male	905	36.24349219	34.3805	38.14875
2020	Stomach	Female	590	37.99098519	35.60946	40.43178
2020	Testis	Male	216	11.66306695	10.27992	13.20492
2020	Urethra	Male	49	12.76041667	9.78829	16.47024
2020	Urethra	Female	10	23.80952381	13.48096	38.52754
2020	Uterus	Female	716	9.299909079	8.671306	9.969107

Urgent suspected cancer referrals

Urgent suspected cancer (USC) referrals are used for people with possible cancer symptoms, to refer them to secondary care for investigation and possible diagnosis. USC referrals used to be called two-week wait referrals due to a previous Cancer Waiting Times (CWT) target that, within two weeks of being referred from their GP, individuals should be seen by a specialist in secondary care.

Urgent suspected cancer referral indicators – NHS Surrey Heartlands ICB vs South East vs England

Source: [OHID Fingertips Cancer Services Profile](#)

Indicator	Period	Surrey Heartlands ICB - QXU			South East	England	England			
		Recent Trend	Count	Value	Value	Value	Lowest	Range	Highest	
Urgent suspected cancer referrals (Indirectly age-gender standardised referral ratio)	2023/24	–	-	-	-	100	75		122	
New cancer cases treated resulting from an urgent suspected cancer referral (Detection rate: % of all new cancer cases treated)	2023/24	➔	3,750	55.7%*	56.9%*	55.7%*	47.7%		63.2%	
Urgent suspected cancer referrals for suspected breast cancer	2023/24	⬆️	9,432	826*	848*	822	626		1,119	
Urgent suspected cancer referrals for suspected lower GI cancer	2023/24	⬆️	10,428	913*	869*	794	465		1,178	
Urgent suspected cancer referrals for suspected lung cancer	2023/24	➔	1,149	101*	104*	113	39		236	
Urgent suspected cancer referrals for suspected skin cancer	2023/24	⬆️	16,806	1,472*	1,188*	1,132	587		2,170	
Urgent suspected cancer referrals resulting in a diagnosis of cancer (Conversion rate: as % of all USC referrals)	2023/24	⬇️	3,667	6.2%*	6.7%*	6.0%*	3.6%		9.1%	
Urgent suspected cancer referrals	2023/24	⬆️	58,970	5,164*	4,948*	4,770	3,464		6,708	
Urgent suspected cancer referrals. Five years combined data.	2019/20 - 23/24	–	245,740	4,472*	4,271*	4,219	3,093		5,691	
Urgent suspected cancer referrals (Indirectly age-gender standardised referral ratio). Five years combined data.	2019/20 - 23/24	–	245,740	102.3*	97.1*	100.0	81.1		117.2	
Urgent suspected cancer referrals resulting in a diagnosis of cancer (Conversion rate: as % of all USC referrals). Five years combined data.	2019/20 - 23/24	–	16,092	6.5%*	7.1%*	6.4%	3.8%		9.0%	
New cancer cases treated resulting from an urgent suspected cancer referral (Detection rate: % of all new cancer cases treated). Five years combined data.	2019/20 - 23/24	–	16,441	55.6%*	55.4%*	54.7%	47.9%		62.6%	
Urgent suspected cancer referrals for suspected breast cancer. Five years combined data.	2019/20 - 23/24	–	41,934	763*	785*	766	588		981	
Urgent suspected cancer referrals for suspected lower GI cancer. Five years combined data.	2019/20 - 23/24	–	49,683	904*	817*	770	473		995	
Urgent suspected cancer referrals for suspected lung cancer. Five years combined data.	2019/20 - 23/24	–	5,664	103*	92*	100	45		183	
Urgent suspected cancer referrals for suspected skin cancer. Five years combined data.	2019/20 - 23/24	–	63,006	1,147*	938*	925	554		1,729	

Urgent suspected cancer referral indicators – NHS Frimley ICB vs South East vs England

Source: [OHID Fingertips Cancer Services Profile](#)



Indicator	Period	Frimley ICB - QNQ			South East	England	England			
		Recent Trend	Count	Value	Value	Value	Lowest	Range	Highest	
Urgent suspected cancer referrals (Indirectly age-gender standardised referral ratio)	2023/24	–	-	75	-	100	75		122	
New cancer cases treated resulting from an urgent suspected cancer referral (Detection rate: % of all new cancer cases treated)	2023/24	↑	2,055	51.1%*	56.9%*	55.7%*	47.7%		63.2%	
Urgent suspected cancer referrals for suspected breast cancer	2023/24	→	6,077	722	848*	822	626		1,119	
Urgent suspected cancer referrals for suspected lower GI cancer	2023/24	↑	5,925	703	869*	794	465		1,178	
Urgent suspected cancer referrals for suspected lung cancer	2023/24	↑	861	102	104*	113	39		236	
Urgent suspected cancer referrals for suspected skin cancer	2023/24	→	4,942	587	1,188*	1,132	587		2,170	
Urgent suspected cancer referrals resulting in a diagnosis of cancer (Conversion rate: as % of all USC referrals)	2023/24	→	2,038	7.0%*	6.7%*	6.0%*	3.6%		9.1%	
Urgent suspected cancer referrals	2023/24	↑	29,258	3,474	4,948*	4,770	3,464		6,708	
Urgent suspected cancer referrals. Five years combined data.	2019/20 - 23/24	–	127,524	3,285	4,271*	4,219	3,093		5,691	
Urgent suspected cancer referrals (Indirectly age-gender standardised referral ratio). Five years combined data.	2019/20 - 23/24	–	127,524	81.1	97.1*	100.0	81.1		117.2	
Urgent suspected cancer referrals resulting in a diagnosis of cancer (Conversion rate: as % of all USC referrals). Five years combined data.	2019/20 - 23/24	–	8,759	6.9%	7.1%*	6.4%	3.8%		9.0%	
New cancer cases treated resulting from an urgent suspected cancer referral (Detection rate: % of all new cancer cases treated). Five years combined data.	2019/20 - 23/24	–	8,854	49.2%	55.4%*	54.7%	47.9%		62.6%	
Urgent suspected cancer referrals for suspected breast cancer. Five years combined data.	2019/20 - 23/24	–	29,007	747	785*	766	588		981	
Urgent suspected cancer referrals for suspected lower GI cancer. Five years combined data.	2019/20 - 23/24	–	25,737	663	817*	770	473		995	
Urgent suspected cancer referrals for suspected lung cancer. Five years combined data.	2019/20 - 23/24	–	3,064	79	92*	100	45		183	
Urgent suspected cancer referrals for suspected skin cancer. Five years combined data.	2019/20 - 23/24	–	24,837	640	938*	925	554		1,729	

GP-registered population

OHID Fingertips report NHS England data on the proportion of the GP registered population (in percent) in the specified age group

Population age profile of GP-registered population by sex and age in NHS Surrey Heartlands ICB and NHS Frimley ICB (2024)

Source: [OHID Fingertips Cancer Services Profile](#)



Population age profile - GP registered population by sex and quinary age band 2024

Age range	NHS Frimley Integrated Care Board - QNQ		South East NHS Region		England	
	Male	Female	Male	Female	Male	Female
0-4	22,022	21,160	234,820	223,145	1,529,486	1,457,071
5-9	25,918	24,361	280,390	266,417	1,799,731	1,712,742
10-14	28,521	26,814	307,422	291,496	1,934,756	1,842,023
15-19	26,881	25,119	296,153	280,995	1,867,630	1,784,924
20-24	23,661	22,814	273,308	270,780	1,890,866	1,911,960
25-29	26,538	26,552	304,430	295,856	2,234,615	2,200,653
30-34	29,399	30,170	333,957	333,958	2,437,008	2,359,214
35-39	32,250	32,391	348,987	346,068	2,437,613	2,319,009
40-44	33,247	32,385	344,246	336,267	2,296,762	2,141,185
45-49	30,521	28,489	316,599	305,421	2,022,829	1,868,471
50-54	29,747	27,850	330,496	321,301	2,090,516	1,981,349
55-59	27,782	26,521	334,041	329,652	2,088,426	2,034,680
60-64	23,803	23,051	301,220	300,309	1,873,268	1,864,397
65-69	18,266	18,630	243,111	252,661	1,508,340	1,559,333
70-74	14,616	16,228	206,187	228,537	1,270,592	1,384,434
75-79	13,341	15,603	199,260	229,902	1,161,330	1,322,806
80-84	8,447	10,303	119,325	149,624	689,477	859,431
85-89	5,030	6,956	69,735	99,441	394,517	563,475
90-94	1,954	3,331	27,292	49,532	147,615	266,742
95+	436	1,112	6,243	16,810	32,214	86,134
All ages	422,380	419,840	4,877,222	4,828,172	31,707,591	31,520,033

Population age profile - GP registered population by sex and quinary age band 2024

Age range	NHS Surrey Heartlands Integrated Care Board - QXU		South East NHS Region		England	
	Male	Female	Male	Female	Male	Female
0-4	27,675	26,478	234,820	223,145	1,529,486	1,457,071
5-9	33,568	32,074	280,390	266,417	1,799,731	1,712,742
10-14	37,017	35,567	307,422	291,496	1,934,756	1,842,023
15-19	35,326	33,481	296,153	280,995	1,867,630	1,784,924
20-24	29,940	29,461	273,308	270,780	1,890,866	1,911,960
25-29	32,371	31,983	304,430	295,856	2,234,615	2,200,653
30-34	35,547	36,505	333,957	333,958	2,437,008	2,359,214
35-39	39,253	40,135	348,987	346,068	2,437,613	2,319,009
40-44	41,789	41,724	344,246	336,267	2,296,762	2,141,185
45-49	41,129	39,676	316,599	305,421	2,022,829	1,868,471
50-54	41,065	39,485	330,496	321,301	2,090,516	1,981,349
55-59	39,809	38,523	334,041	329,652	2,088,426	2,034,680
60-64	35,163	34,243	301,220	300,309	1,873,268	1,864,397
65-69	27,014	27,789	243,111	252,661	1,508,340	1,559,333
70-74	22,557	24,964	206,187	228,537	1,270,592	1,384,434
75-79	21,721	25,110	199,260	229,902	1,161,330	1,322,806
80-84	13,242	17,290	119,325	149,624	689,477	859,431
85-89	8,156	12,024	69,735	99,441	394,517	563,475
90-94	3,533	6,386	27,292	49,532	147,615	266,742
95+	878	2,233	6,243	16,810	32,214	86,134
All ages	566,753	575,131	4,877,222	4,828,172	31,707,591	31,520,033

Proportion of GP-registered population age 65+ by PCN (2024)

Source: [OHID Fingertips Cancer Services Profile](#)

Areas **All in NHS Surrey Heartlands Integrated Care Board - QXU** All in England

Show 99.8% CI values

Area	Recent Trend	Count	Value
England	→	11,246,440	17.8
NHS Surrey Heartlands Integrated Care Board - QXU	→	212,897	18.6
Leatherhead PCN	→	10,444	23.5*
Banstead Healthcare PCN	→	11,309	23.4*
Dorking PCN	→	10,560	23.3*
West of Waverley PCN	→	10,932	23.0*
South Tandridge PCN	→	7,812	22.4*
East Waverley PCN	→	13,564	22.2*
WB PCN	→	6,453	21.0*
Sasse Network 1 PCN	→	10,845	20.9*
Guildford East PCN	→	11,959	20.3*
Cobham and Oxshott PCN	→	4,221	19.3*
Integrated Care Partnership PCN	→	6,127	19.3*
Woking Wise 1 PCN	→	5,741	18.8*
Healthy Horley PCN	→	8,239	18.3*
Epsom PCN	→	11,208	18.1*
North Tandridge PCN	→	6,729	18.0*
Wham PCN	→	8,493	17.9*
East Elmbridge PCN	→	11,072	17.9*
COCO PCN	→	7,843	17.4*
Sasse Network 2 PCN	→	6,803	16.7*
Walton Practices Confederation PCN	→	3,506	15.8*
Redhill Phoenix PCN	→	4,643	15.7*
Woking Wise 3 PCN	→	5,251	15.3*
Sasse Network 3 PCN	→	6,792	14.9*
Care Collaborative (Redhill) PCN	→	7,378	14.6*
Woking Wise 2 PCN	→	5,854	13.4*
Central and North Guildford PCN	→	8,844	13.1*

Source: NHS England

[Indicator Definitions and Supporting Information](#)

Area	Recent Trend	Count	Value
England	→	11,246,440	17.8
NHS Frimley Integrated Care Board - QNQ	→	134,253	15.9
Yateley PCN	→	6,601	22.4*
Ascot PCN	→	6,997	21.7*
Surrey Heath PCN	→	19,969	19.4*
Fleet PCN	→	9,499	19.2*
Farnham PCN	→	8,686	19.2*
Maidenhead PCN	→	13,390	17.8*
The Health Triangle PCN	→	9,145	17.2*
Windsor PCN	→	11,576	16.6*
Farnborough PCN	→	10,205	16.4*
Braccan PCN	→	4,566	14.7*
Aldershot PCN	→	7,506	14.6*
Bracknell and District PCN	→	5,389	13.8*
Spine PCN	→	4,488	10.3*
Central Slough Network PCN	→	5,784	10.0*
Shape PCN	→	2,793	9.7*
LOCC PCN	→	4,239	8.0*

Source: NHS England

[Indicator Definitions and Supporting Information](#)

Cancer screening coverage and uptake

National cancer screening programmes are offered across Surrey for breast, bowel and cervical cancers. Lung cancer screening is currently being rolled out across the county as part of the national expansion of Targeted Lung Cancer Screening. There are shared and pathway specific inequalities in uptake detailed in the [Surrey Screening JSNA](#).

Topline take-homes: variations in cancer screening coverage

Source: OHID Fingertips (2024 proportion)

By District & Borough: Cancer screening coverage in the following Districts and Boroughs is significantly below the England and/or Surrey Heartlands average for one or more of the respective screening programmes:

D&B	Breast	Bowel	Cervical (25-49)	Cervical (50-64)
Elmbridge	Below England and SH	Below SH	Similar to SH	Below England and SH
Epsom & Ewell	Similar to SH	Below SH	Below SH	Below England and SH
Guildford	Similar to SH	Similar to SH	Below England and SH	Similar to SH
Runnymede	Below England and SH	Similar to SH	Below SH	Below SH
Spelthorne	Below England and SH	Below SH	Below SH	Below SH
Woking	Below England and SH	Below SH	Below England and SH	Below SH

Topline take-homes: variations in cancer screening coverage

Source: OHID Fingertips (2023/23 proportion)

By PCN: Cancer screening coverage in the following PCNs is significantly below the England and/or Surrey Heartlands average for one or more of the respective screening programmes:

PCN	Breast	Bowel	Cervical (25-49)	Cervical (50-64)	Serves key neighbourhood?
Central and North Guildford	Below SH	Below SH	Below England and SH	Below England and SH	
Cobham and Oxshott	Below England and SH	Below SH	Below SH	Below England and SH	
COCO	Below England and SH	Below SH	Similar to SH	Similar to SH	16. Runnymede OO6D (Chertsey St Anns)
East Elmbridge	Below England and SH	Similar to SH	Similar to SH	Similar to SH	
Epsom PCN	Similar to SH	Similar to SH	Below SH	Similar to SH	8. Epsom and Ewell 007A (Court)
Healthy Horley	Below SH	Similar to SH	Similar to SH	Similar to SH	1. Reigate / Banstead 008A (Hooley, Merstham & Netherne)
Integrated Care Partnership	Similar to SH	Similar to SH	Below SH	Below England and SH	
North Tandridge	Below SH	Similar to SH	Similar to SH	Similar to SH	
Sasse Network 1	Below SH	Similar to SH	Similar to SH	Similar to SH	
Sasse Network 2	Below England and SH	Below SH	Similar to SH	Similar to SH	
Sasse Network 3	Below England and SH	Below England and SH	Below England and SH	Below England and SH	5. Spelthorne 001B and C (Stanwell North) 9. Spelthorne 002C (Ashford North and Stanwell South)
Walton Practices Confederation	Similar to SH	Below England and SH	Below SH	Below England and SH	12. Elmbridge 004B (Walton South) 19. Elmbridge 008A (Walton North)
Woking Wise 2	Below England and SH	Below SH	Below SH	Similar to SH	
Woking Wise 3	Below England and SH	Similar to SH	Below England and SH	Below England and SH	2. Woking 004F (Canalside) 10. Woking 005B (Goldsworth Park)

Breast screening (2024 coverage – proportion) – by Surrey District and Borough

Source: OHID Fingertips

Cancer screening coverage: breast cancer New data 2024 Proportion - %

[Show me the profiles these indicators are from](#)

[Legend](#)
[Benchmark](#)
[More options](#)

Geography version

Areas All in Surrey All in England

[Show 99.8% CI values](#)

Area <input type="button" value="▲▼"/>	Recent Trend	Count <input type="button" value="▲▼"/>	Value <input type="button" value="▲▼"/>		95% Lower CI	95% Upper CI
England	→	4,618,157	69.9*	<div style="width: 69.9%; background-color: #6c757d;"></div>	69.9	69.9
Surrey	→	101,163	71.1*	<div style="width: 71.1%; background-color: #28a745;"></div>	70.9	71.4
Mole Valley	↑	8,911	76.1	<div style="width: 76.1%; background-color: #28a745;"></div>	75.4	76.9
Surrey Heath	→	8,329	75.3	<div style="width: 75.3%; background-color: #28a745;"></div>	74.5	76.1
Waverley	→	11,902	75.0	<div style="width: 75.0%; background-color: #28a745;"></div>	74.3	75.7
Reigate and Banstead	→	12,550	73.4	<div style="width: 73.4%; background-color: #28a745;"></div>	72.7	74.0
Guildford	→	11,778	72.8	<div style="width: 72.8%; background-color: #28a745;"></div>	72.1	73.5
Epsom and Ewell	↓	6,495	70.5	<div style="width: 70.5%; background-color: #ffc107;"></div>	69.5	71.4
Tandridge	→	7,811	70.5	<div style="width: 70.5%; background-color: #ffc107;"></div>	69.6	71.3
Elmbridge	↓	11,457	67.5	<div style="width: 67.5%; background-color: #dc3545;"></div>	66.8	68.2
Spelthorne	↓	7,949	66.8	<div style="width: 66.8%; background-color: #dc3545;"></div>	65.9	67.6
Woking	↓	7,502	66.4	<div style="width: 66.4%; background-color: #dc3545;"></div>	65.5	67.3
Runnymede	→	6,479	66.0	<div style="width: 66.0%; background-color: #dc3545;"></div>	65.1	67.0

Source: NHS England, Breast Screening Programme

[Indicator Definitions and Supporting Information](#)

Coverage in Runnymede, Woking, Spelthorne and Elmbridge significantly lower than Surrey and national average (71.1%) (95% confidence intervals)

Bowel cancer screening (2024 coverage – proportion) – by Surrey District and Borough

Source: OHID Fingertips

Cancer screening coverage: bowel cancer New data 2024 Proportion - %

[Show me the profiles these indicators are from](#)

[Legend](#)
[Benchmark](#)
[More options](#)

Geography version Districts & UAs (from Apr 2023) ▾

Areas All in Surrey All in England

[Show 99.8% CI values](#)

Area ▲▼	Recent Trend	Count ▲▼	Value ▲▼	95% Lower CI	95% Upper CI
England	↑	6,764,895	71.8*	71.8	71.8
Surrey	↑	147,188	74.4*	74.2	74.6
Waverley	↑	17,256	77.3	76.7	77.8
Surrey Heath	↑	11,754	76.2	75.5	76.9
Mole Valley	↑	13,040	76.0	75.4	76.7
Guildford	↑	16,936	76.0	75.4	76.6
Tandridge	↑	11,845	75.5	74.9	76.2
Reigate and Banstead	↑	17,726	74.5	73.9	75.1
Epsom and Ewell	↑	9,365	73.6	72.8	74.3
Woking	↑	11,306	72.4	71.7	73.1
Elmbridge	↑	16,294	72.1	71.5	72.7
Runnymede	↑	9,768	71.6	70.8	72.3
Spelthorne	↑	11,898	71.4	70.7	72.1


Source: NHS England, Bowel Cancer Screening Programme

[Indicator Definitions and Supporting Information](#)

Coverage in Spelthorne, Runnymede, Elmbridge, Woking and Epsom and Ewell significantly lower than Surrey average, but similar to national average (71.8%)

Cervical screening, age 25-49 years (2024 coverage – proportion) – by Surrey District and Borough

Source: OHID Fingertips




Coverage in Guildford, Woking, Runnymede, Epsom and Ewell, and Spelthorne significantly lower than Surrey average (69.0%); and Guildford and Woking significantly lower than national average (66.1%) using 95% confidence intervals. Trend data indicating a recent decrease in coverage in 6 of 11 Districts and Boroughs in Surrey.

Source: NHS England, Cervical Screening Programme
[Indicator Definitions and Supporting Information](#)

Cervical screening, age 50-64 years (2024 coverage – proportion) – by Surrey District and Borough

Source: OHID Fingertips



Coverage in **Elmbridge, Epsom and Ewell, Woking, Spelthorne** and **Runnymede** significantly lower than Surrey average (74.9%) based on 95% confidence intervals. Elmbridge and Epsom and Ewell significantly lower than national average. Recent trend data indicating stable coverage in most districts and boroughs except Epsom and Ewell and Woking, where it is decreasing

Source: NHS England, Cervical Screening Programme

[Indicator Definitions and Supporting Information](#)

Breast screening age 53-70 years (2023/2024 coverage – proportion) – by Surrey PCN

Source: OHID Fingertips

Breast screening coverage in 7 PCNs in Surrey Heartlands ICB was significantly lower than the England and Surrey Heartlands average (Woking Wise 2 and 3 PCNs, COCO PCN, Sasse Network 2 and 3 PCNs, Cobham and Oxshott PCN and East Elmbridge). The following PCNs are similar to the England average, but fall below the Surrey Heartlands average: North Tandridge, Central and North Guildford PCN, Healthy Horley PCN and Sasse Network 1 .

[Legend](#) [Benchmark](#) [More options](#)

Geography version PCNs (v. 25/10/24)

Areas All in Surrey Heartlands ICB - 92A All in England

[Show 95% CI values](#)

Area	Recent Trend	Count	Value	99.8% Lower Ci	99.8% Upper Ci
England	–	4,625,845	69.9	69.8	70.0
Surrey Heartlands ICB - 92A	–	86,420	71.3	70.9	71.7
Leatherhead PCN	–	4,190	79.4*	77.6	81.0
East Waverley PCN	–	5,310	78.0*	76.4	79.5
Redhill Phoenix PCN	–	2,225	77.5*	75.0	79.8
Banstead Healthcare PCN	–	4,515	76.4*	74.6	78.1
Guildford East PCN	–	5,400	75.9*	74.3	77.5
Dorking PCN	–	4,265	74.5*	72.7	76.2
Epsom PCN	–	4,475	72.7*	70.9	74.4
West of Waverley PCN	–	4,295	72.6*	70.7	74.3
Woking Wise 1 PCN	–	2,300	72.3*	69.8	74.7
Care Collaborative (Redhill) PCN	–	3,395	71.8*	69.7	73.8
WB PCN	–	2,315	71.5*	68.9	73.8
South Tandridge PCN	–	2,970	71.0*	68.8	73.1
Wham PCN	–	3,435	70.6*	68.5	72.6
Integrated Care Partnership PCN	–	2,505	69.7*	67.3	72.0
Sasse Network 1 PCN	–	4,040	69.4*	67.5	71.2
Walton Practices Confederation PCN	–	1,460	68.5*	65.4	71.6
Healthy Horley PCN	–	3,195	68.5*	66.4	70.6
Central and North Guildford PCN	–	3,615	68.5*	66.5	70.4
North Tandridge PCN	–	2,750	68.4*	66.1	70.6
East Elmbridge PCN	–	4,805	67.3*	65.5	69.1
Woking Wise 3 PCN	–	2,195	67.0*	64.4	69.5
Cobham and Oxshott PCN	–	1,610	66.7*	63.6	69.6
Sasse Network 2 PCN	–	2,835	66.4*	64.1	68.6
Sasse Network 3 PCN	–	2,860	66.1*	63.9	68.3
COCO PCN	–	3,105	66.0*	63.8	68.1
Woking Wise 2 PCN	–	2,450	64.9*	62.5	67.3

Source: NHS England, Breast Screening Programme

[Indicator Definitions and Supporting Information](#)

[Legend](#) [Benchmark](#) [More options](#)

Geography version PCNs (v. 25/10/24)

Areas All in Frimley ICB - D4U1Y All in England

[Show 95% CI values](#)

Area	Recent Trend	Count	Value	99.8% Lower Ci	99.8% Upper Ci
England	–	4,625,845	69.9	69.8	70.0
Frimley ICB - D4U1Y	–	60,380	73.0	72.5	73.4
Yateley PCN	–	2,715	78.0*	75.8	80.1
The Health Triangle PCN	–	4,255	76.9*	75.1	78.6
Bracknell and District PCN	–	2,895	76.4*	74.2	78.4
Fleet PCN	–	3,990	75.9*	74.1	77.7
Surrey Heath PCN	–	8,570	75.7*	74.5	77.0
Windsor PCN	–	5,215	75.6*	74.0	77.2
Braccan PCN	–	2,550	74.8*	72.4	77.0
Farnham PCN	–	3,615	74.7*	72.7	76.6
Maidenhead PCN	–	5,675	74.7*	73.1	76.2
Ascot PCN	–	3,105	74.5*	72.3	76.5
Farnborough PCN	–	4,820	73.6*	71.9	75.3
Aldershot PCN	–	3,380	69.9*	67.8	71.9
Shape PCN	–	1,355	65.3*	62.0	68.5
LOCC PCN	–	2,080	61.6*	59.0	64.2
Central Slough Network PCN	–	2,575	61.2*	58.8	63.5
Spine PCN	–	2,025	59.1*	56.5	61.7


Source: NHS England, Breast Screening Programme

[Indicator Definitions and Supporting Information](#)


Bowel cancer screening (2023/2024 coverage – proportion) – by Surrey PCN

Source: OHID Fingertips

Bowel cancer screening coverage in 2 PCNs in Surrey Heartlands ICB was significantly lower than the England and Surrey Heartlands average (Walton Practices Confederation, and Sasse Network 3). The following PCNs are similar to the England average, but fall below the Surrey Heartlands average: Cobham and Oxshott PCN, Woking Wise 2 PCN, Sasse Network 2 PCN, COCO PCN, Central and North Guildford PCN.



Source: NHS England, Bowel Cancer Screening Programme
Indicator Definitions and Supporting Information



Source: NHS England, Bowel Cancer Screening Programme
Indicator Definitions and Supporting Information

Cervical screening, age 25-49 years (2023/24 coverage – proportion) – by Surrey PCN

Source: OHID Fingertips

Cervical screening coverage (women aged 25-49) in 3 PCNs in Surrey Heartlands ICB was significantly lower than the England and Surrey Heartlands average (Central and North Guildford PCN, Woking Wise 3 PCN, Sasse Network 3 PCN). The following PCNs are similar to the England average, but fall below the Surrey Heartlands average: Integrated Care Partnership PCN, Cobham and Oxshott PCN, Woking Wise 2 PCN, Walton Practices Confederation, Epsom PCN).

Areas **All in Surrey Heartlands ICB - 92A** All in England

Show 95% CI values

Area	Recent Trend	Count	Value	99.8% Lower CI	99.8% Upper CI
England	↓	7,289,450	67.5	67.4	67.5
Surrey Heartlands ICB - 92A	↓	133,065	70.4*	70.1	70.8
South Tandridge PCN	↑	3,950	76.9*	75.1	78.7
North Tandridge PCN	→	4,905	76.9*	75.2	78.5
Guildford East PCN	↓	6,685	76.1*	74.7	77.5
Banstead Healthcare PCN	→	5,320	75.0*	73.4	76.5
Dorking PCN	→	4,925	74.6*	72.9	76.2
Wham PCN	→	6,030	74.5*	73.0	76.0
East Waverley PCN	↓	6,855	74.3*	72.8	75.6
Leatherhead PCN	↑	4,810	74.2*	72.5	75.9
West of Waverley PCN	→	4,850	73.2*	71.4	74.8
WB PCN	↓	3,595	73.0*	71.0	74.9
Healthy Horley PCN	↓	5,640	72.7*	71.1	74.2
Care Collaborative (Redhill) PCN	→	6,965	72.5*	71.1	73.9
Sasse Network 1 PCN	→	6,055	72.2*	70.6	73.7
COCO PCN	↑	5,725	71.6*	70.0	73.1
East Elmbridge PCN	→	6,965	70.9*	69.5	72.3
Sasse Network 2 PCN	→	4,970	69.2*	67.5	70.8
Woking Wise 1 PCN	↓	3,405	69.1*	67.1	71.1
Redhill Phoenix PCN	→	3,770	69.0*	67.1	70.9
Epsom PCN	↓	7,405	69.0*	67.6	70.4
Walton Practices Confederation PCN	→	2,740	67.4*	65.1	69.6
Woking Wise 2 PCN	→	5,820	67.0*	65.4	68.6
Cobham and Oxshott PCN	→	2,035	66.0*	63.3	68.5
Integrated Care Partnership PCN	↓	3,230	65.6*	63.5	67.6
Sasse Network 3 PCN	↓	5,355	63.3*	61.7	64.9
Woking Wise 3 PCN	↓	3,885	62.8*	60.8	64.6
Central and North Guildford PCN	↓	7,040	58.6*	57.2	60.0

Source: NHS England, Cervical Screening Programme

Indicator Definitions and Supporting Information

Indicator
Cervical screening coverage: aged 25 to 49 years old 2023/24 Proportion - %

Legend Benchmark More options

Geography version PCNs (v. 25/10/24)

Areas **All in Frimley ICB - D4U1Y** All in England

Show 95% CI values

Area	Recent Trend	Count	Value	99.8% Lower CI	99.8% Upper CI
England	↓	7,289,450	67.5	67.4	67.5
Frimley ICB - D4U1Y	↓	104,020	69.8	69.5	70.2
Yateley PCN	→	3,600	78.0*	76.1	79.8
Fleet PCN	→	6,025	76.7*	75.2	78.1
Farnborough PCN	→	8,385	72.8*	71.6	74.1
Farnham PCN	↓	5,135	72.0*	70.3	73.6
Bracknell and District PCN	↓	5,325	71.8*	70.1	73.4
Surrey Heath PCN	↓	12,290	71.6*	70.5	72.6
Maidenhead PCN	→	9,360	71.0*	69.8	72.2
The Health Triangle PCN	↓	6,715	71.0*	69.6	72.4
Braccan PCN	↓	4,005	70.9*	69.0	72.8
Ascot PCN	↓	3,140	70.8*	68.6	72.9
Aldershot PCN	↓	7,195	70.1*	68.6	71.4
Shape PCN	→	3,670	69.0*	67.0	70.9
Windsor PCN	→	7,650	68.5*	67.2	69.9
LOCC PCN	→	7,225	65.1*	63.7	66.5
Spine PCN	→	5,205	61.3*	59.7	62.9
Central Slough Network PCN	↓	7,005	61.0*	59.6	62.4

Source: NHS England, Cervical Screening Programme

Indicator Definitions and Supporting Information

Cervical screening, age 50-64 years (2023/24 coverage – proportion) – by Surrey PCN

Source: OHID Fingertips

Cervical screening coverage (women aged 50-64) in 5 PCNs in Surrey Heartlands ICB was significantly lower than the England and Surrey Heartlands average (Cobham and Oxshott PCN, Walton Practices Confederation, Integrated Care Partnership PCN, Woking Wise 3, Sasse Network 3 PCN. Central and North Guildford PCN, PCN,) . All other PCNs were similar to or better than the Surrey Heartlands average.

Indicator: Cervical screening coverage: aged 50 to 64 years old 2023/24 Proportion - %

Legend Benchmark More options

Geography version: PCNs (v. 25/10/24)

Areas: All in Surrey Heartlands ICB - 92A All in England

Show 95% CI values

Area	Recent Trend	Count	Value	99.8% Lower CI	99.8% Upper CI
England	→	4,066,260	74.9	74.8	74.9
Surrey Heartlands ICB - 92A	→	80,090	75.6	75.2	76.0
Guildford East PCN	→	5,020	80.4	78.8	81.9
North Tandridge PCN	→	2,830	80.1	77.9	82.1
Banstead Healthcare PCN	↑	3,810	77.7	75.8	79.5
South Tandridge PCN	→	2,745	77.2	75.0	79.3
WB PCN	→	2,150	77.2	74.7	79.6
West of Waverley PCN	→	3,910	76.9	75.0	78.7
Leatherhead PCN	→	3,400	76.7	74.7	78.7
East Waverley PCN	→	4,355	76.4	74.6	78.1
COCO PCN	↑	3,080	76.2	74.1	78.2
Sasse Network 1 PCN	→	3,750	75.9	74.0	77.7
Care Collaborative (Redhill) PCN	↑	3,260	75.7	73.7	77.7
Redhill Phoenix PCN	→	1,965	75.6	72.9	78.1
Woking Wise 1 PCN	↓	2,085	75.5	72.9	78.0
Healthy Horley PCN	→	2,935	75.4	73.3	77.5
Epsom PCN	→	4,145	75.3	73.5	77.0
Dorking PCN	→	3,640	75.3	73.3	77.2
Sasse Network 2 PCN	→	2,835	75.2	73.0	77.3
East Elmbridge PCN	↑	4,785	75.0	73.3	76.6
Wham PCN	→	3,375	74.8	72.7	76.7
Central and North Guildford PCN	→	3,320	74.2	72.1	76.2
Woking Wise 2 PCN	→	2,570	73.9	71.5	76.1
Sasse Network 3 PCN	→	2,760	72.5	70.2	74.7
Woking Wise 3 PCN	↓	2,075	72.0	69.4	74.6
Integrated Care Partnership PCN	↓	2,245	71.0	68.5	73.5
Walton Practices Confederation PCN	→	1,390	70.4	67.1	73.5
Cobham and Oxshott PCN	→	1,575	70.3	67.2	73.2

Source: NHS England, Cervical Screening Programme

Indicator Definitions and Supporting Information

Indicator: Cervical screening coverage: aged 50 to 64 years old 2023/24 Proportion - %

Legend Benchmark More options

Geography version: PCNs (v. 25/10/24)

Areas: All in Frimley ICB - D4U1Y All in England

Show 95% CI values

Area	Recent Trend	Count	Value	99.8% Lower CI	99.8% Upper CI
England	→	4,066,260	74.9	74.8	74.9
Frimley ICB - D4U1Y	↓	54,825	76.4	75.9	76.9
Shape PCN	→	1,560	80.0	77.1	82.6
Fleet PCN	→	3,750	79.2	77.3	81.0
Yateley PCN	→	2,165	79.0	76.5	81.3
Farnham PCN	→	3,310	78.5	76.5	80.4
Maidenhead PCN	→	5,035	77.3	75.6	78.8
Windsor PCN	→	4,745	77.3	75.6	78.9
The Health Triangle PCN	→	3,545	77.1	75.1	78.9
Surrey Heath PCN	→	7,335	76.8	75.4	78.1
Farnborough PCN	→	4,185	76.4	74.6	78.2
Central Slough Network PCN	↓	2,825	76.2	74.0	78.3
Ascot PCN	→	2,790	76.1	73.9	78.2
Bracknell and District PCN	↓	2,515	75.3	72.9	77.5
Braccan PCN	→	2,175	74.6	72.0	77.0
Aldershot PCN	↓	2,985	73.8	71.6	75.9
LOCC PCN	→	2,325	72.9	70.4	75.2
Spine PCN	→	2,165	69.1	66.5	71.5

Source: NHS England, Cervical Screening Programme

Indicator Definitions and Supporting Information